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On the Involvement of the Low-Density Lipoprotein Receptor in the 
Pathogenesis and Progression of Alzheimer’s Disease 
 
Jose Francisco Abisambra Socarras 
 
ABSTRACT  
 
 
 
  Alzheimer’s disease (AD) is the most prevalent form of age-
associated dementia. Cholesterol dysregulation is linked with AD onset. 
Besides age, the most important risk factor associated with AD is the 
inheritance of the ε-4 allele of apolipoprotein E, a cholesterol transporter. 
In addition, while hypercholesterolemia has been shown to be an 
independent risk factor for AD, the nature of the cholesterol-AD link is 
still not clear. This gap in our understanding is partly due to a lack of 
knowledge about cholesterol metabolism in the central nervous system 
(CNS).  
 
 The low-density lipoprotein receptor (LDLR) is the main receptor of 
apoE and a central regulator of serum cholesterol levels. Therefore, we 
 vii 
 
sought to characterize the potential participation of LDLR in AD 
pathogenesis and/or progression. Previous reports with similar aims came 
to contradictory conclusions. Such studies assessed potential changes in 
AD in the absence of LDLR by utilizing the LDLR-/- mouse model and 
crossing it to AD mouse models.  
 
 Initially we evaluated LDLR-/- mice as a suitable model to study AD. 
We found that LDLR-/- mice overexpressed a functional splice-variant of 
LDLR, LDLR∆4. Moreover, its protein localized in similar regions as the 
LDLR did in control mice. Finally, we determined that LDLR∆4 bound 
apoE, which underscores the impact of the isoform’s function in the CNS.  
 
 We then focused on characterizing changes to LDLR in AD models. 
We found that APP overexpression in cells increased LDLR mRNA and 
protein. APP overexpression and Aβ treatment shifted LDLR localization. 
An AD mouse model showed increased LDLR in hippocampus. Conversely, 
LDLR levels were decreased in APP-/- mice. Finally, we found that 
microtubules were affected in cells overexpressing APP. 
 
 In conclusion, the data presented argue for the importance of LDLR-
mediated regulation of cholesterol during AD progression. Also, LDLR may 
 viii 
 
participate in the initial pathogenic insults leading to amyloid deposition, 
which make it a potential therapeutic target to treat AD. Finally, we 
propose that APP/Aβ overexpression disrupts microtubule formation; this 
alteration affects protein trafficking. One of the proteins affected is LDLR, 
the repercussions of which may ultimately result in cholesterol 
dysregulation.  
 
 
  
 
 
NANOS GIGANTIUM HUMERUS INSIDENTES 
(Dwarves standing on the shoulders of giants) 
-Bernard de Chartres 
 
Scientific progress cannot be achieved without the strong 
foundation edified by other scientists. It is from the past that aspiring 
scientists like myself find inspiration to formulate our own hypotheses. 
The work in this dissertation is inspired by elegant reports written by 
scientists who exercised ingenuity, rigorous methodology, and astute 
interpretation in the fields of heart disease and Alzheimer’s disease. 
These two devastating diseases have marred the lives of millions 
throughout the world. Thusly, the research of these ailments demands 
the intensity and perseverance these giants have dedicated. 
 
In 1901, while director of the state asylum of Frankfurt am Main, 
the psychiatrist and neuropathologist Alois Alzheimer met and treated 
Auguste D. She had been referred to the asylum for suffering from 
behavioral disorders characterized by progressive memory loss, irritation, 
and disorientation. After her death in 1905, Alzheimer performed an 
 2 
 
autopsy and described in 1906 the major hallmarks of the disease that 
today bears his name: neurodegeneration, amyloid plaques, and 
neurofibrillary tangles. This description is still used today to confirm 
Alzheimer’s disease diagnoses, underscoring the importance of Alois 
Alzheimer’s discovery.   
 
While investigating the root causes of familial hypercholesterolemia 
(FH), Michael Brown and Joseph Goldstein discovered the low-density 
lipoprotein receptor (LDLR), the main protein responsible for removing 
LDL cholesterol from the blood torrent. They concurrently described what 
is known today as the LDLR pathway, which includes a general step in the 
import of substances inside cells termed receptor-mediated endocytosis.  
 
Brown and Goldstein’s astute strategy was to analyze the genetic 
makeup of individuals from families who suffered from high serum 
cholesterol levels. They found mutations in the LDLR gene that rendered 
the receptor unable to function in separate steps of its metabolic cycle. 
As a result, the patients’ ability to remove LDL from the blood was 
impaired, leading to hypercholesterolemia and subsequent sequelae.  
 
Brown and Goldstein were awarded the Nobel Prize in Physiology or 
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Medicine in 1985 for these discoveries. Their strategy is used in the 
research of other diseases including AD, and has revealed important 
mutations that are involved in the disease process. The mutant forms of 
several human genes that cause or promote familial Alzheimer’s disease 
have been introduced into the genome of transgenic mice, which serve 
today as the most common in vivo model for AD research.   
 
Without exception, I based the hypotheses and methods contained 
in this dissertation on the findings of many other researchers. I’ve had 
the unique opportunity to be a scientist during a very exciting time. The 
resources available today added to our own intellectual efforts produced 
the results presented in this dissertation. The experimental design and 
data presentation contain the signature of our own ingenuity to reveal 
the results presented herein. Conclusions derived from these results 
required careful analysis. This is our contribution. I hope that our results 
will feed the body of knowledge upon which other scientists will discover 
relevant information that may lead to strategies and approaches targeted 
to reduce or eliminate the suffering caused by AD. 
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INTRODUCTION 
 
Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder 
and the most common cause of dementia (Schoenberg, Kokmen, & 
Okazaki, 1987). AD patients are characterized by a loss of or decrease in 
memory, which is accompanied by a decline in at least one of the 
following cognitive abilities: (1) generation of coherent speech as well as 
understanding written language; (2) identification of objects; (3) 
execution of motor tasks; and (4) capability to form abstract thought, 
make sound judgment, and plan and carry out complex tasks 
(Association, 2008). To meet these criteria, the patient must have intact 
motor and sensory systems, and must understand the tasks he or she is 
asked to perform.  
 
According to the Alzheimer’s Association’s 2008 Alzheimer’s Disease 
Facts and Figures report, 5.2 million people in the United States suffer 
from AD, and it accounts for 70% of dementias in people age 71 or older. 
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Furthermore, 50% of the population over 85 years of age suffers from 
AD.  
 
Onset of AD after age 65 is defined as late-onset or sporadic AD, 
which accounts for over 95% of the AD population and has an idiopathic 
etiology with some genetic contribution. Early-onset AD, which 
constitutes less than 1% of the remaining AD population, has a well-
characterized genetic etiology, whereby specific mutations lead to 
autosomal dominant inheritance of ‘familial’ AD, and it typically ensues 
under the age of 65. Epidemiological studies show that AD is more 
prevalent in women, in people who have fewer years of education, and in 
African Americans.  
 
 Despite its first description over one hundred years ago, there is 
still no cure for AD. However, reports that AD patients have severely 
reduced levels of acetylcholine (Ach), a key memory-associated 
neurotransmitter, triggered the development of pharmacological 
approaches to modulate Ach (Bartus, Dean, Beer, & Lippa, 1982; Coyle, 
Price, & DeLong, 1983; Davies & Verth, 1977; Gaykema, et al., 1992). 
Pharmacological modulation of acetylcholine transmission would be 
expected to diminish the decline in learning and memory. In fact, it has 
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been reported that there is mild cognitive improvement (Giacobini, 
1997). One approach is to reduce or inhibit acetyl cholinesterase (AchE) 
activity, which increase Ach levels and aid in improving learning and 
memory. Unfortunately, cognitive improvements are only mild due to 
short half-life and adverse side effects, which restrict their use (Forsyth, 
et al., 1989; Tariot, et al., 2000; Watkins, Zimmerman, Knapp, Gracon, & 
Lewis, 1994). Donepezil hydrochloride (Aricept) has been the most 
effective AchE inhibitor and is commonly used to treat AD patients 
(Rogers, Doody, Mohs, & Friedhoff, 1998). 
 
Cardiovascular disease and AD share many risk factors and 
correlates (Reid, Urano, Kodama, & Hamakubo, 2007), such as 
hypercholesterolemia (Soneira & Scott, 1996) and atherosclerosis 
(Hofman, et al., 1997; Kalback, et al., 2004; Reid, et al., 2007), 
hypertension (Skoog, et al., 1996), and diabetes type 2 (Ott, et al., 
1996). Consequently, statins, cholesterol-lowering drugs, have been 
evaluated as therapeutic agents to treat AD. However, so far the results 
are inconclusive (Dufouil, et al., 2005; Rea, et al., 2005; Sjogren, et al., 
2003; Sparks, Connor, Browne, Lopez, & Sabbagh, 2002; Sparks, 
Martins, & Martin, 2002; Wolozin, Kellman, Ruosseau, Celesia, & Siegel, 
2000; Zamrini, McGwin, & Roseman, 2004; Zandi, et al., 2005). 
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The Mini Mental-State Exam (MMSE) is used to evaluate subjects 
who begin to present symptoms of cognitive impairment. During the past 
few years, I had the opportunity volunteer at the Johnnie B. Byrd, Sr. 
Alzheimer’s Center and Research Institute Clinic to evaluate the cognitive 
status of Spanish-speaking individuals using the MMSE. I found that in 
the initial stages of cognitive decline patients often present emotional 
distress in the form of depression, frustration, and irritability. These signs 
further exacerbate symptoms of dementia due to ensuing apathy, which 
leads to hypoprosexia or loss of attention. Patients in advanced stages of 
AD or other types of dementia are typically apathetic. It was in these 
cases where it became evident that the caregivers were the burdened 
victims.  
 
Inasmuch as the disease causes harm to patients, social and 
economic burdens are intimately related. Direct and indirect costs of the 
disease in the US have risen to over $148 billion annually. This figure 
does not account for an estimated $89 billion provided by the 10 million 
caregivers in unpaid services to AD patients (Association, 2008). This 
fiscal hemorrhage burdens State and Federal economies. The urgency for 
the discovery of effective therapeutic interventions is increasing as “baby 
boomers” reach the age of AD onset, which is estimated to amount to 10 
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million people over the upcoming decades (Association, 2008). By 2050, 
it is estimated that the incidence of AD will reach one million persons per 
year and a prevalence of 11 to 16 million. Therefore, these costs are 
likely to widen the hole in the U.S. healthcare system as well as debilitate 
the efforts in place for the current economic recovery. 
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Alzheimer’s Disease Pathology 
 
The Clinical signs of Alzheimer dementia are the result of 
neurodegeneration, which is rooted in the build up of extracellular 
amyloid or senile plaques and intracellular neurofibrillary or tau tangles 
(Kidd, 1963). Alois Alzheimer recognized these structures in the brain 
sections of Auguste D. Plaques and tangles are similar in that they are 
aggregated protein complexes that deposit due to their highly 
unstructured and hydrophobic nature. However, they differ in their 
proteinaceous components and the pathways through which they 
conglomerate.  
 
The etiological hypotheses of AD pathogenesis have divided the 
field into two groups that have been jocularly named “Tau-ists” and 
“βAPP-tists” (Tanzi & Parson, 2000). The former contend that the seeding 
pathogenic insult is the formation of tangles. Part of the argument is 
rooted in the fact that the amount of tangles directly correlates with the 
degree of dementia (Alafuzoff, Iqbal, Friden, Adolfsson, & Winblad, 
1987), which is not true of amyloid plaques. The βAPP-tists make 
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compelling arguments based on the findings that mutations in the genes 
coding for amyloid precursor protein (APP) (Ancolio, et al., 1999; 
Chartier-Harlin, et al., 1991; Eckman, et al., 1997; Goate, et al., 1991; 
Hendriks, et al., 1992; Mullan, et al., 1992; Murrell, Farlow, Ghetti, & 
Benson, 1991) and presenilin (Levy-Lahad, et al., 1995; Rogaev, et al., 
1995; Sherrington, et al., 1995) have been identified in patients with 
familial AD. Also, there is an APP gene-dosage effect leading to AD or AD-
like symptoms in Down’s syndrome (DS) individuals, who eventually will 
suffer from AD after their fourth decade of life (Rumble, et al., 1989; K. 
E. Wisniewski, Wisniewski, & Wen, 1985). Since the APP gene is in 
chromosome 21, DS individuals carry an extra copy of this gene, thereby 
increasing the amount of APP. Although recent evidence indicates that 
plaque deposition antecedes tangle formation (Gotz, Chen, van Dorpe, & 
Nitsch, 2001; J. Lewis, et al., 2001), it is not yet clear whether 
treatments would be most effective by targeting the clearance of plaques 
or tangles and when during the course of the disease, such treatments 
should be initiated.  
 
The most popular hypothesis of AD pathogenesis is known as the 
amyloid cascade, which states that Aβ generation is the initial pathogenic 
step leading to neurodegeneration and dementia (Hardy & Higgins, 
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1992). Experimental evidence in transgenic mouse models indicates that 
Aβ deposition is antecedent to tangle formation. Alternative hypotheses 
propose pacifying theories contending, for instance, that both hallmarks 
are the result of similar pathogenic pathways or that plaques and tangles 
are not the major pathogenic culprits in AD but rather by-products of a 
more upstream insult to the CNS that accumulates over time. 
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Amyloid Precursor Protein 
 
Amyloid deposits at the center of senile plaques are the result of 
abnormal processing of the amyloid precursor protein (APP) (Kang, et al., 
1987). In this process, APP is coordinately cleaved by two enzymes, β- 
and γ-secretase. In this amyloidogenic pathway, the APP protein 
generates a 38-42 amino acid peptide termed Aβ. The most toxic peptide 
product is Aβ42, and it is capable of self-aggregation into oligomers of 
varying lengths including fibrils (Lambert, et al., 1998). The β-pleated 
sheet structure of this peptide makes it more prone for aggregation. 
 
Other proteins can catalyze Aβ aggregation. Non-classical 
chaperones, like apolipoprotein E (apoE) (Costa, Nilsson, Bales, Paul, & 
Potter, 2004; Howland, et al., 1998) and anti-chymotrypsin (ACT) 
(Abraham, Selkoe, & Potter, 1988), bind Aβ and are thought to promote 
its deposition into amyloid. However, the notion that plaques are 
responsible of neurotoxicity is currently being reevaluated.  
Overwhelming data indicate that it is not plaques that cause the 
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pathogenic insult leading to AD, but rather the Aβ oligomers themselves 
that induce neurodegeneration (Hartley, et al., 1999; Hsia, et al., 1999; 
Lambert, et al., 1998; Lemere, et al., 1996; Mucke, et al., 2000; Walsh, 
et al., 2002). 
 
The APP gene is located on chromosome 21q21.2-3, and it codes 
for three major isoforms of 770, 751, and 695 amino acids (Kitaguchi, 
Takahashi, Tokushima, Shiojiri, & Ito, 1988). APP695 lacks a 56-residue 
Kunitz protease inhibitor sequence that is present in the other two 
isoforms. Furthermore, APP770 has a 19 amino acid sequence of unknown 
function that is absent in APP751. Although the three isoforms can be 
made in many tissues and cells, the comparative ratios with which they 
are generated are different according to the type of tissue or sub-region 
within the tissue, and the special circumstances under which the tissue is 
stimulated, such as specific developmental stages or disease. For 
instance, the brain mainly favors expression of APP695 (Tanaka, et al., 
1988), but cultured human astrocytes and hippocampal rat astrocytes 
preferentially make APP770 and APP751 (Gray & Patel, 1993; Rohan de 
Silva, et al., 1997). So far, there is no definitive explanation for these 
differences.  
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APP is found in many membrane-associated structures in the cell, 
and it can be processed in more than one location. Notably, APP has been 
detected in the endoplasmic reticulum (Tomimoto, Akiguchi, Wakita, 
Nakamura, & Kimura, 1995), several Golgi compartments (Caporaso, et 
al., 1994; Tomimoto, et al., 1995), the cell membrane (Tomimoto, et al., 
1995), and lysosomes (Haass, Koo, Mellon, Hung, & Selkoe, 1992). 
Furthermore, APP deposits have been observed to be associated with 
specific molecules in synaptic vesicles, in postsynaptic membranes of 
axons and dendrites (Schubert, et al., 1991; Shigematsu, McGeer, & 
McGeer, 1992), and coupled to membrane rafts (Bouillot, Prochiantz, 
Rougon, & Allinquant, 1996; Hayashi, Mizuno, Michikawa, Haass, & 
Yanagisawa, 2000).  
 
A great deal of research is devoted to characterizing the normal 
function of APP as a means to understand the pathogenesis of AD. APP 
has been shown to assume the role of a G-protein-coupled receptor due 
to its intracellular association with G0 in in vitro experiments (Brouillet, et 
al., 1999). Also, many APP-binding partners participate in cell adhesion 
and motility, which suggests that APP is also involved in these processes 
(Breen, 1992; M. Chen & Yankner, 1991; Sabo, Ikin, Buxbaum, & 
Greengard, 2001). However, the physiological function of APP and its 
 15 
 
cleavage products is still poorly understood. Conversely, a lot is known 
about APP’s breakdown product Aβ, due to its participation in Alzheimer’s. 
AD pathogenesis is the result of increased levels of Aβ42, which in FAD 
can be due to mutations on the genes coding for APP and/or the enzymes 
that process APP. These enzymes have been termed secretases as the 
products of their proteolytic activity are secreted, and they have been 
catalogued based on the target site on APP, namely α-, β-, and γ-
secretases. 
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α-secretase 
 
APP cleavage can undergo non-amyloidogenic processing, whereby 
α-secretase cleaves within the Aβ sequence (termed the α-site), 
hampering formation and subsequent release of the fully formed toxic Aβ 
peptide. The resulting product is a soluble species named sAPPα, which 
corresponds to the large ectodomain of APP. Normally, this is the main 
product of APP processing in the body (Hooper, 2005); however, in AD 
patients, sAPPα is significantly decreased in cerebro-spinal fluid (CSF) 
(Lannfelt, Basun, Wahlund, Rowe, & Wagner, 1995; Van Nostrand, et al., 
1992). The α-secretase activity is dependent upon the distance of the 
cleavage site to the membrane, and the secondary helix structure 
(Sisodia, 1992). Both of these conditions can be altered by FAD 
mutations.  
 
Protein kinase C (PKC) activators and metabotropic glutamate 
receptor agonists induce cleavage of APP at the α-site (Kirazov, Loffler, 
Schliebs, & Bigl, 1997; Nitsch, Deng, Wurtman, & Growdon, 1997). Since 
 17 
 
these stimuli activate a large number of enzymes, it has been suggested 
that APP is not the only substrate for an α-secretase. Instead, three 
enzyme candidates may in fact be α-secretase (Hooper, 2005):  tumor 
necrosis factor-α converting enzyme (TACE/ADAM17) (Black, et al., 
1997; Moss, et al., 1997), ADAM9, and ADAM10 (reviewed in (Allinson, 
Parkin, Turner, & Hooper, 2003)). Nonetheless, there is no confirmation 
of these findings. Promotion of α-cleavage on APP is an attractive 
therapeutic goal currently underway. However, this requires development 
of specific α-secretase agonists, since substances like PKC activators have 
wide-range targets. 
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β-secretase 
 
Pathogenic, Aβ-forming pathway of APP processing is executed by 
β- and γ-secretases’ cleavage at the amino and carboxy-termini of the Aβ 
peptide, respectively. There are two homologue β-secretases, BACE1 
(Vassar, et al., 1999; Yan, et al., 1999) and BACE2 (Farzan, Schnitzler, 
Vasilieva, Leung, & Choe, 2000) (β-site APP-cleaving enzymes), and they 
are membrane-bound, aspartyl proteases that target APP. Their location, 
expression, and activity differ (Bennett, et al., 2000). BACE1 is found in 
many tissues, however particularly in brain and pancreas. In the CNS, 
BACE1 is mainly produced in neurons, while very low levels are 
detectable in glia (Vassar, et al., 1999). These data correlate with 
functional studies that show elevated products of BACE1-specific activity 
on APP in cortical neurons (Sinha, et al., 1999). On the contrary, BACE2 
expression in the brain is notably lower than in peripheral tissues such as 
colon, stomach, and thyroid gland (Bennett, et al., 2000). In the CNS, 
BACE2 mRNA levels are virtually undetectable except in neurons of the 
ventromedial hypothalamus and the mamillary body (Bennett, et al., 
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2000). BACE2 activity is less prevalent than the pathogenic BACE1 
cleavage, which takes place at the amino terminus of Aβ and renders a 
soluble and extracellular fragment of APP, sAPPβ.  
 
The product of BACE1 processing of APP is a membrane-bound 
carboxy-terminal fragment, APP-CTFβ, which is then available for γ-
secretase to cleave at the carboxy-terminus of Aβ. This toxic peptide is 
then released. In contrast, BACE2 cleaves at the β-site in a non-
amyloidogenic manner within the Aβ peptide sequence. Therefore, Aβ 
generation is hampered (Farzan, et al., 2000). Therapeutic interventions 
to increase BACE2’s activity on the non-pathogenic target on APP are 
currently underway (Farzan, et al., 2000). 
 
Like in the case of α-secretase, full-length APP is not the only 
substrate for β-secretases (Liu, Doms, & Lee, 2002). Nevertheless, 
BACE1’s pathogenic processing of APP is increased in AD patients where 
its levels and activity are elevated. This risk is particularly high in 
individuals carrying the Swedish mutation because BACE1 can cleave 
APPSw with significantly greater specificity than alternate forms of APP 
(Yan, et al., 1999).  
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γ-secretase 
 
The γ-site on APP is cleaved by γ-secretase, a complex enzyme 
made up of four components, presenilin (PS), nicastrin (NCT), aph-1, and 
pen-2. After β–secretase cleavage, γ-secretase processing of APP 
generates the Aβ peptide. PS is an aspartyl protease that can incorporate 
one of two homologous catalytic subunits, PS1 (Cruts, et al., 1995) and 
PS2 (J. Li, Ma, & Potter, 1995). They have eight transmembrane domains 
(TMD), and the active site resides between the sixth and seventh TMD (X. 
Li & Greenwald, 1998). It is here where the two ASP required of aspartyl 
protease activity are located. Mutation analyses showed that replacing 
the aspartate for alanine reduced production of Aβ (Wolfe, et al., 1999). 
This relationship had remained elusive due to the intra-membranous 
location of the γ-site. Further progress in the identification of other intra-
membranous cleavages provided support for this obscure proteolytic 
activity termed regulated intra-membrane proteolysis (RIP) (Lee, et al., 
2002; Ni, Murphy, Golde, & Carpenter, 2001; Sakai, et al., 1996; 
Schroeter, Kisslinger, & Kopan, 1998). 
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Aspartyl proteases contain the D(T/S)G(T/S) consensus sequence 
in the active site. Interestingly, PSs have a GxGD (where x is any amino 
acid) in place of the D(T/S)G(T/S) residues in the active site. The GxGD 
motif is also conserved in other enzymes that perform RIP, like type-4 
prepilin peptidases (Steiner, et al., 2000) and signal peptide peptidases 
(discussed in (Weihofen & Martoglio, 2003)). It has therefore been 
suggested that these proteins form a new family of aspartyl-proteases 
whose specialized intra-membranous cleavage activity requires a 
modified sequence from the consensus aspartyl peptidase site (Haass & 
Steiner, 2002).  
 
Linkage analyses identified over 100 mutations leading to some of 
the most common and aggressively progressing FAD pathologies in the 
PS genes. Mice with the PS2 gene knocked out (PS2-/-) show no 
significant change in phenotype from wild-type controls, except for mild 
pulmonary fibrosis and increased ease of hemorrhage over time 
(Herreman, et al., 1999). APP processing is not affected in these mice, 
leading to the assumption that: (1) PS2 may play a minor role regarding 
APP cleavage and (2) AD mutations on PS2 are gain-of-function 
mutations. In contrast, PS1-/- mice show severe developmental 
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deficiencies reminiscent of the Notch1-/- phenotype (discussed later) 
(Herreman, et al., 1999), suggesting that PS1 plays a more 
physiologically relevant role (Herreman, et al., 1999).  
 
As stated previously, PS is a component of the γ-secretase complex. 
As such, and based on experiments in different in vivo and in vitro 
models, it’s γ-site cleavage activity is dependent upon the other four 
components (Francis, et al., 2002). NCT has been mostly characterized 
under scrutiny of its role in γ-secretase activity, and it has been shown to 
be indispensable for secretase function (Edbauer, Winkler, Haass, & 
Steiner, 2002; Hu, Ye, & Fortini, 2002; Leem, et al., 2002). Knockdown 
and knockout experiments targeting NCT preclude maturation of the γ-
secretase complex (Edbauer, et al., 2002) and reduce or abolish 
enzymatic activity (Hu, et al., 2002). Furthermore, PS1-/- cells exhibit 
reduced levels of mature NCT, suggesting that NCT maturation is 
dependent on its interaction with PS1 (Edbauer, et al., 2002). Genetic 
screens in C. elegans identified aph-1 (Goutte, Tsunozaki, Hale, & Priess, 
2002) and pen-2 (Francis, et al., 2002) as critical elements for γ-
secretase function. Moreover, pen-2 was found to co-immunoprecipitate 
with NCT implying that it formed the γ-secretase complex (Steiner, et al., 
2002).  
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These two proteins were quickly recognized as having important 
roles in Notch processing, another substrate of γ-secretase cleavage. 
Reduction of γ-secretase activity by downregulation or elimination of any 
component of the complex results in a phenotype similar to the Notch-/- 
models (discussed in (Haass & Steiner, 2002)). As briefly mentioned 
above, Notch signaling pathway plays a key role in development. The 
study of the molecular mechanisms driving this pathway revealed the γ-
secretase-mediated cleavage, or S3, of Notch to release a Notch 
intracellular domain (NICD). This newly formed peptide translocates into 
the nucleus and functions as an activator of gene transcription. Likewise, 
the γ-secretase cleavage of APP releases an APP intracellular domain 
(AICD) that is thought to have transactivating properties like NICD. AICD 
promoter elements have not been completely identified. Together, these 
two mechanisms underscore the way by which γ-secretase targets type-1 
membrane proteins and release an S3 transcription factor. Other recently 
identified proteins that undergo γ-secretase proteolysis are the APP 
homolog APLP1, Notch 2-4, ErbB-4, E-Cadherin, CD44, Nectin1α, and LRP 
(Haass & Steiner, 2002). However, the exact downstream effects of these 
cleavages have not been conclusively characterized. 
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Tau 
 
The other major pathological hallmark present in AD brains is the 
presence of neurofibrillary tangles (NFT), made of paired-helical filaments 
(PHF) or τ-tangles. These structures are intracellular deposits of a 
filamentous protein whose basic subunit is a toxic, misfolded, and 
hyperphosphorylated τ (Grundke-Iqbal, et al., 1986; Iqbal, et al., 1974; 
Kosik, Joachim, & Selkoe, 1986). Normally, as a microtubule-associated 
protein (MAP), τ promotes elongation and stabilization of microtubules. 
The human brain is capable of making six splice variants of τ (Goedert, 
Spillantini, Jakes, Rutherford, & Crowther, 1989), which are mainly 
phosphorylated by several kinases like glycogen synthase kinase-3 
(GSK3) (Ishiguro, et al., 1993). Conversely, several phosphatases have 
also been detected as modifiers of τ. Together, these enzymes keep a 
balance of active and inactive τ to stabilize polymerization of tubulin into 
microtubules. Interestingly, two of these enzymes, protein phosphatases 
PP-2A and PP-1, are reduced in AD brains, resulting in τ-
hyperphosphorylation (Gong, Grundke-Iqbal, & Iqbal, 1994; Gong, Singh, 
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Grundke-Iqbal, & Iqbal, 1993). While τ phosphorylation permits 
disassociation for microtubule breakdown, self-aggregation and 
deposition of τ is triggered by hyperphosphorylation. This pathogenic 
hyperphospho-τ form is not only incapable of promoting the formation 
and stabilization of microtubules, but it also sequesters normal τ as well 
as other microtubule stabilizers such as MAP1 and MAP2 (Alonso, 
Grundke-Iqbal, & Iqbal, 1996; Alonso, Zaidi, Grundke-Iqbal, & Iqbal, 
1994). The end result is inhibition and disruption of tubulin 
polymerization (Alonso, et al., 1994).  
 
Pathogenic τ is present in two cellular pools: PHF and cytosolic 
hyperphosphorylated τ. While the former is inert and incapable of binding 
tubulin (Iqbal, Zaidi, Bancher, & Grundke-Iqbal, 1994); the latter 
comprises 40% of the pathogenic τ. The cytosolic portion is the most 
pathogenic as it is free to inhibit microtubule formation and stabilization 
by impairing microtubule-associated proteins 1 and 2, and endogenous, 
non-pathogenic tau (Alonso, et al., 1996; Alonso, et al., 1994; B. Li, 
Chohan, Grundke-Iqbal, & Iqbal, 2007). Although AD brains have the 
same amount of non-pathogenic τ as those of non-diseased individuals, 
toxic τ levels are increased four to eight-fold in AD brains compared to 
those of non-AD individuals (Khatoon, Grundke-Iqbal, & Iqbal, 1992, 
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1994).  
Since amyloid deposition seems to precede formation of PHF (Gotz, 
et al., 2001; J. Lewis, et al., 2001), τ has been thought to be a 
downstream component of toxicity and thusly less effective as a 
therapeutic target. However, other neurodegenerative diseases fronto-
temporal dementia, progressive supranuclear palsy, corticobasal 
degeneration, and Pick’s disease, are called tauopathies as they are also 
characterized by having NFT. The identification of τ as a component in the 
pathology of these diseases underscores the toxic impact of τ in AD 
dementia. In fact, as opposed to amyloid plaques, the amount of tangles 
correlates better with the clinical diagnosis and degree of dementia in AD 
patients (Arriagada, Growdon, Hedley-Whyte, & Hyman, 1992); patients 
burdened with Aβ-plaques without the tangle component lack signs of 
dementia (Arriagada, et al., 1992; Dickson, et al., 1988; Katzman, et al., 
1988).  
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Cholesterol and the Risk of Alzheimer’s Disease 
 
Cholesterol is vital to life because it is an essential component of 
cell membranes, it is the starting molecule from which steroid hormones 
originate, and it produces the bile for absorption of other fatty acids 
necessary for life. In cell membranes, cholesterol provides rigidity that 
can be used for protein docking, formation of lipid rafts, and to become 
part of vesicles that will either be fused or evacuated from the plasma 
membrane. Cholesterol is constantly shed from the cell membrane and 
actively replenished so that the net amount of cholesterol in a cell 
membrane remains constant. To maintain this equilibrium, a constant 
cholesterol supply needs to be maintained. To meet this requirement, 
almost every tissue in the body is capable of making and/or internalizing 
cholesterol.  
 
Elucidation of the pathways for biosynthesis, degradation, and 
cycling of cholesterol has revealed the function of proteins that are 
directly or indirectly involved in regulating cholesterol. Therefore, 
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identification of some of these proteins in the CNS has allowed swift 
strides in understanding how cholesterol is regulated in the brain. Some 
of these players are the cholesterol transporter, apoE, and its main 
receptors: LDLR, LRP (LDLR-related protein), VLDLR (very LDLR), and 
apoER2 (Pitas, Boyles, Lee, Hui, & Weisgraber, 1987). However, the 
differences between both peripheral and central compartments relay 
distinctions between these players. For instance, the main cholesterol 
transporter in CNS is apoE, whereas in the periphery there are many 
other apolipoproteins that play a significant role in cholesterol circulation 
such as apoB and apoA. The brain makes its own apoE that is 
independent from the plasmatic pool (Linton, et al., 1991); and it also 
differs in structure (Pitas, Boyles, Lee, Foss, & Mahley, 1987).  
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Cholesterol Metabolism in the Brain 
 
 There is no experimental evidence proving that peripheral 
cholesterol crosses to the CNS. Several studies concluded that lipoprotein 
cholesterol did not cross the CNS at any age or region of the CNS. In 
effect, 125I-labeled-LDL injected intravenously was virtually undetectable 
in CNS of adult mice, sheep, and rabbit, while the liver and adrenal gland 
took up LDL from 100 to 1000 µl/h/g (Osono, Woollett, Herz, & Dietschy, 
1995; Spady, Huettinger, Bilheimer, & Dietschy, 1987). The same 
observation was found in sheep at both the fetal and suckling stages, 
which coincide with a very high level of cholesterol accretion due to brain 
growth and myelination (Turley, Burns, Rosenfeld, & Dietschy, 1996). 
Similar results were found with 14C-labeled cholesteryl esters in HDL, 
providing evidence that CNS impermeability to lipoproteins is not unique 
to LDL (reviewed in (Dietschy & Turley, 2004)). Other efforts to find 
potential pathways of cholesterol transport from serum to the brain have 
been disproven. For instance, there was no change in CNS cholesterol 
content or synthesis when deleting brain lipoprotein transporters like 
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LDLR (Dietschy, Kita, Suckling, Goldstein, & Brown, 1983; Osono, et al., 
1995), SR-BI, or ABCA1 (Quan, Xie, Dietschy, & Turley, 2003). Finally, 
increasing serum cholesterol by dietary means did not change the 
cholesterol content in the CNS (Quan, et al., 2003). Therefore, 
cholesterol metabolism in the CNS seems to be independent from 
peripheral input.  
 
This conclusion can be explained in part by the presence of the 
blood-brain barrier (BBB) a cell-layered structure of unique endothelial 
cells that cover every capillary irrigating the CNS and selectively filters 
substances for entry to the CNS. Moreover, podocytic processes on 
astrocytes adjacent to the endothelial cells form tight junctions further 
reducing fenestrae and minimizing capillary exchange (Rubin & Staddon, 
1999). Unlike other body regions where molecules can diffuse 
paracellularly, permeable substances to the BBB must face the 
endothelial cells parallel to the capillary (Stewart & Hayakawa, 1987). 
The result is an obstreperous, highly selectively permeable cellular 
membrane that protects the CNS by regulating the amount and type of 
molecules that can come in contact with neural tissue. Selective 
permeability is facilitated via specific transport proteins (Rubin & 
Staddon, 1999); furthermore, like most membranes in the body, the BBB 
 31 
 
is permeable to water, and therefore some hydroxylated substances are 
also capable of diffusing through to the CNS.  
 
Evaluation of cholesterol transport across the BBB performed during 
development yielded similar conclusions. Experiments in developing and 
adult rats, baboons, and humans show that labeled cholesterol 
administered intravenously, intragastrically, or by ingestion in the diet 
was detected in peripheral organs like liver and adrenal glands; however, 
such exogenous cholesterol was not detected above background in the 
brain (Chobanian & Hollander, 1962; Edmond, Korsak, Morrow, Torok-
Both, & Catlin, 1991; Wilson, 1970; G. Xu, et al., 1998). Since its 
cholesterol requirement is vast and serum cholesterol is unable to form a 
part of the brain’s sterol pool, the CNS must produce its own cholesterol 
supply (Dietschy & Turley, 2004). For example, cholesterol synthesis has 
been measured to be high in oligodendrocytes at the time of intensive 
myelin formation during development (Fu, et al., 1998; H. Jurevics, 
Bouldin, Toews, & Morell, 1998; H. A. Jurevics & Morell, 1994). This 
effect correlates with myelin formation in the periphery, where Schwann 
cells synthesize the cholesterol used to form myelin in axonic and 
dendritic prolongations. Moreover, the rate of synthesis decreases as the 
organism reaches adulthood (H. Jurevics & Morell, 1995; Muse, Jurevics, 
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Toews, Matsushima, & Morell, 2001; Quan, et al., 2003). Presumably, 
this occurs as myelin formation has culminated (Dietschy & Turley, 
2004). During this stage of life, cholesterol accretion is lower than that of 
synthesis, indicating that the net movement of cholesterol is towards 
excretion. However, it has also been suggested that the disparity 
between synthesis and accretion is due to basal maintenance of glial and 
neuronal membranes (Spady & Dietschy, 1983). The uniqueness of CNS 
cholesterol synthesis is also seen in that there is no evidence that CNS-
synthesized cholesterol is packaged in lipoproteins (Dietschy & Turley, 
2004).    
 
The net flow of cholesterol exits the CNS into plasma, but in order 
to cross the BBB, sterols must be modified to become permeable. The 
enzyme cholesterol 24-hydroxylase (CYP46A1) is capable of modifying 
cholesterol into a permeable molecule, 24(S)-hydroxycholesterol 
(Dietschy & Turley, 2004). Both the detection of mRNA for CYP46A1 
almost exclusively in the CNS (Lund, et al., 2003; Lutjohann, et al., 
1996) as well as identification of 24(S)-hydroxycholesterol’s capacity of 
exiting the BBB from the CNS (Lutjohann, et al., 1996) suggested a 
method of sterol flow from CNS to plasma. Once in serum, 24(S)-
hydroxycholesterol enters the liver where its conversion to bile acids and 
 33 
 
subsequent excretion takes place (Bjorkhem, et al., 2001). Levels of 
24(S)-hydroxycholesterol in the developing mouse correlate with the 
initial decline in cholesterol synthesis in CNS (Lund, Guileyardo, & 
Russell, 1999). Interestingly, mRNA for CYP46A1 was mostly found in 
neurons located in areas where the highest levels of myelin formation 
takes place, suggesting that it is this type of cell that regulates 
cholesterol turnover at the end of brain development (Lund, et al., 1999). 
This observation further supports the excretion pathway of cholesterol 
and contributes to the model of net cholesterol flow from the CNS during 
different ages in the mouse. 
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Cholesterol and Disease 
 
 Cholesterol’s function as a delimiting component of plasma 
membrane and thereby its role as a mediator in cell-to-cell or cell-to-
milieu interactions, make it subject to a wide range of pathogenic insults. 
Specifically, as a component of liquid-ordered, detergent-resistant 
membrane rafts (lipid rafts), cholesterol docks proteins that can be 
intrinsic to the membrane, doubly acylated, palmitoylated, or anchored 
by glycophosphatidyl inositol (GPI). These proteins perform a vast 
number of functions for cell survival, development, or homeostasis. 
Alterations to cholesterol in these membranes undoubtedly cause insults 
to the cellular balance and, in most extreme cases, cause disease. Some 
examples of diseases resulting from alterations to cholesterol in rafts are 
AD, Parkinson’s disease, Niemann-Pick disease, diabetes, neoplasia, 
atherosclerosis, B and T-cell response, asthma, and prion diseases, 
among many others (K. Simons & Ehehalt, 2002).  
 
 Genetic disorders inducing hypocholesterolemia further underscore 
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the importance of cholesterol in brain development. Smith-Lemli-Optiz 
syndrome is characterized by the inability of patients to procure 
cholesterol. As a result, multisystemic alterations ensue, such as 
pulmonary deficit due to the inability to produce lung surfactant. Also, 
neurodevelopment is altered, and these patients are characterized by 
mental retardation (Salen, et al., 1996). Less severe cases where 
cholesterol fluctuations occur have been postulated as the root causes of 
behavioral diseases. For instance, low serum cholesterol levels have been 
related to suicidal, criminal, and aggressive behavior and has led to the 
hypothesis that reduced serum cholesterol may in turn reduce serotonin, 
a hormone involved in behavior (Engelberg, 1992). In effect, these 
individuals have lower serum serotonin levels (Engelberg, 1992; Muldoon, 
Manuck, & Matthews, 1990). Also, hyper and hypocholesterolemia are 
associated with all-cause mortality. Too high or too low cholesterolemia is 
directly proportional to non-violent mortality rates (Iribarren, Reed, 
Chen, Yano, & Dwyer, 1995; Jacobs, 1993; Muldoon, et al., 1990; 
Peterson, Trell, & Sternby, 1981). However, these latter hypotheses are 
based on association and have not been molecularly linked.   
 
AD and atherosclerosis are discussed below. Associations between 
cholesterol and these two diseases are population based, and their links 
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have been further studied using animal models. 
 
 
Cholesterol and Atherosclerosis 
 
Cholesterol’s reputation has been besmirched by its role in 
cardiovascular disease. Excess cholesterol from the diet leads to 
atherosclerosis, a condition where lipid deposits laminate and eventually 
obstruct the lumen of blood vessels (Small & Shipley, 1974). The result is 
reduction in blood supply to the region where arteries (at the capillary 
portion) irrigate. Atherosclerosis is especially damaging when it occurs in 
the coronary arteries that feed the heart since their occlusion mainly 
results in myocardial infarction and, in severe cases, leads to death 
(Keys, 1975).  
 
The population consuming western diets, where total concentration 
of cholesterol is 300-500 mg of cholesterol/day (Berenson, et al., 1992; 
L. A. Lewis, et al., 1957) compared to <100 mg of cholesterol/day in 
Amerindians, tribes in Papua New Guinea, and rural Chinese is at high 
risk for the fatal consequences of coronary occlusion (Z. Chen, et al., 
1991; Connor, et al., 1978; Dietschy & Turley, 2004; McMurry, 
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Cerqueira, Connor, & Connor, 1991; McMurry, Connor, Lin, Cerqueira, & 
Connor, 1985; Mendez, Tejada, & Flores, 1962; Sinnett & Whyte, 1973; 
Whyte & Yee, 1958). As a result, these factors have prompted extensive 
investigation of peripheral cholesterol metabolism. However, though 
common, atherosclerosis-induced cerebro-vascular accidents have been a 
second plane of cholesterol research. Consequently, there is poor 
understanding of cholesterol homeostasis in the CNS.  
 
Hypercholesterolemia is not only found as a consequence of diet, 
but also from genetic predisposition. The most commonly studied form of 
hypercholesterolemia is the latter condition, where a series of mutations 
that affect proteins involved in cholesterol metabolism were analyzed. 
Familial hypercholesterolemia (FH), an autosomal dominantly inherited 
disease, is caused by mutations in a gene encoding a particular protein 
called the LDLR. This receptor has the highest binding affinity for 
apolipoprotein E (apoE). FH mutations lead to a reduction or ablation of 
LDLR function, resulting in hypercholesterolemia. Patients who are 
homozygous for FH mutations have no functional LDLR; this severe form 
of the disease leads to early mortality typically by way of acute 
myocardial infarction. 
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Cholesterol and Alzheimer’s Disease 
 
 Cholesterol has been portrayed as an important link to AD 
pathogenesis because 1) apolipoprotein E4, a cholesterol transporter, is 
the main molecular risk factor for both AD and atherosclerosis (Corder, et 
al., 1993); 2) hypercholesterolemia is an independent risk factor, as 
increased levels of LDL-cholesterol in mid-life correlate with higher risk 
for AD (Notkola, et al., 1998); 3) cognitively intact individuals with signs 
of heart disease show prevalent amyloid plaque load compared to age-
matched individuals without cardiovascular ailment (Sparks, et al., 
1990); 4) AD patients have higher LDL, which correlate with Aβ levels 
(Kuo, et al., 1998); 5) protective proteins against cardiovascular disease, 
like HDL and apoA1, are decreased in AD patients(Merched, Xia, Visvikis, 
Serot, & Siest, 2000); 5) Aβ production can be manipulated by modifying 
the pools of membrane cholesterol (Fassbender, et al., 2001; M. Simons, 
et al., 1998); 6) brains of rabbits fed a high-cholesterol diet present Aβ 
deposits (Sparks, et al., 1994); 7) atherogenic diets accelerate Aβ 
deposition in AD transgenic mice (Levin-Allerhand, Lominska, & Smith, 
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2002; Refolo, et al., 2000; Shie, Jin, Cook, Leverenz, & LeBoeuf, 2002); 
and 8) atherosclerotic lesions and cognitive decline correlate with Aβ load 
in transgenic AD mice backcrossed to a strain that is susceptible to 
formation of atheromas (L. Li, Cao, Garber, Kim, & Fukuchi, 2003). Other 
preliminary observations include the finding that individuals treated with 
cholesterol-lowering drugs are at lower risk of AD (Buxbaum, Cullen, & 
Friedhoff, 2002; Sjogren, et al., 2003); however, these results are 
contradicted and remain unconfirmed (Fassbender, et al., 2002; M. 
Simons, et al., 2002).  Studies carried out in vitro conclude that 
cholesterol plays a role in modulating Aβ generation. Treatment of HEK 
293 cells stably expressing full-length APP with lovastatin reduces 
intracellular cholesterol by 50% and virtually inhibits secretion of 
amyloidogenic products from APP cleavage (Frears, Stephens, Walters, 
Davies, & Austen, 1999). Meanwhile, treatment of the same cells with 
exogenous cholesterol induces a 4-fold increase in total secreted 
amyloidogenic products and decreased products of APP cleavage by α-
secretase (Bodovitz & Klein, 1996; Frears, et al., 1999). Interestingly, 
while 1.8-fold of the increased amyloidogenic species correspond to Aβ40, 
Aβ42 levels are decreased (Frears, et al., 1999) in the media. Cholesterol 
reduces glycosylation and consequently the cleavage of APP into non-
pathogenic products (Galbete, et al., 2000). Cellular vesicle transport is 
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reduced when exposed to pathogenic Aβ; this alteration is replicated by 
treatment with low levels of extracellular cholesterol. Together, these 
studies indicate that exogenous cholesterol provokes Aβ production and 
reduces α-secretase cleavage products. However, the exact mechanisms 
are unclear. These studies measure APP-products in the media, yet 
intracellular Aβ42 is unaccounted upon cholesterol-induced production of 
Aβ. It can be inferred that Aβ42 may cause intracellular toxicity leading to 
cell death. 
 
 Overall, the elucidation of cholesterol’s involvement in 
neurodegenerative diseases has been elusive and this is partly due to the 
difficulty of accessing the CNS in vivo for analytical studies. Nevertheless, 
several groups have evaluated 24(S)-hydroxycholesterol as a measure of 
cholesterol efflux during disease (Bjorkhem & Meaney, 2004) and in the 
case of AD, it was found that there is an initial increase in serum 24(S)-
hydroxycholesterol (Heverin, et al., 2004; Papassotiropoulos, et al., 
2002; Papassotiropoulos, et al., 2000; Schonknecht, et al., 2002). Other 
studies revealed that CYP46A1 expression is shifted ectopically from 
neurons to glia in AD patients, which should result in decreased 24(S)-
hydroxycholesterol (Bogdanovic, et al., 2001; J. Brown, 3rd, et al., 
2004). The conflict in these results can be settled by underscoring the 
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timing between these measurements, as an initial peak of 24(S)-
hydroxycholesterol could be the result of demyelination, while the 
reduction in CYP46A1 expression could be the result of neuronal loss, as 
it is neurons that make this enzyme. Ultimately, AD patients have 
increased serum levels of another oxysterol that can evacuate the CNS by 
a CYP46A1-independent pathway. Conversion of cholesterol to 27-
hydroxycholesterol is presumed to be accountable for the major sterol 
excretion from the CNS seen in AD. Unfortunately, there is a lack in 
confirmatory reports or even studies deepening the understanding of 
cholesterol flow during neurodegenerative diseases (Dietschy & Turley, 
2004).  
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Apolipoprotein E Isoforms and Disease 
 
ApoE is a 34 kDa, 299-amino acid glycoprotein and is the chief 
cholesterol transporter in the central nervous system (CNS). In the 
periphery, apoE is a major component of VLDL. Aside from its 
involvement in cholesterol transport, apoE also participates in peripheral 
nerve recovery, pathogenic chaperoning of Aβ (T. Wisniewski & 
Frangione, 1992), and signal transduction by way of the various 
receptors it is able to bind (Strittmatter, 2001).  
 
The APOE gene, located on chromosome 19q13, may code for any 
homozygote or heterozygote combination of three isoforms—apoE2, 
apoE3, and apoE4 (Havel & Kane, 1973; Zannis, Just, & Breslow, 1981). 
Structure-function differences between the apoE isoforms increase the 
risk for several diseases. The E4 isoform of apoE is the strongest 
molecular risk factor for AD onset. It is estimated that 60% of LOAD 
cases are attributable to the apoE4 isoform (Rubinsztein & Easton, 1999), 
and about 60-80% of all AD patients have at least one copy of apoE4 
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(Mahley, Weisgraber, & Huang, 2006; Saunders, et al., 1993; 
Strittmatter, et al., 1993). Furthermore, the risk for AD is increased in an 
allelic dose-dependent manner where two copies of apoE4 result in higher 
risk than any other isoform combination (Corder, et al., 1993).  
 
The isoforms differ in both the frequencies with which they are 
found in the population as well as in the primary structure in amino acids 
112 and 158: apoE2 (frequency of 2-5%) has a cysteine in each one of 
these sites; apoE3 is the most common (65-70%) and has Cys-112 and 
Arg-158; finally, apoE4 (15-20%) has two arginines at these sites (Rall, 
Weisgraber, & Mahley, 1982; Weisgraber, Rall, & Mahley, 1981). 
Structural differences affect the lipid content of the isoforms, where Arg-
112 on E4 makes it more favorable for carrying large, triglyceride-rich 
VLDL particles, rather than smaller phospholipids on HDL. Furthermore, 
the apoE4 substitutions elicit a stronger interaction between the C-
terminal and N-terminal domains, rendering a more compact structure 
than apoE3 (Mahley, 1988; Mahley & Rall, 2000; Weisgraber, 1994).  
 
In the CNS, apoE-cholesterol is principally made in astrocytes and 
exported to neurons (Boyles, Pitas, Wilson, Mahley, & Taylor, 1985; 
Elshourbagy, Liao, Mahley, & Taylor, 1985); however, neurons can also 
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produce apoE-cholesterol during stress (Q. Xu, et al., 2006). Despite 
expressing several receptors that are capable of internalizing apoE, such 
as low-density lipoprotein receptor (LDLR), LDLR-related protein (LRP), 
apoER2, and VLDLR, neurons mainly import apoE via the LDLR 
(Innerarity & Mahley, 1978; Innerarity, Pitas, & Mahley, 1979; Mahley, 
1988; Mahley & Rall, 2000).  
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Low-Density Lipoprotein Receptor (LDLR) and Disease 
 
While investigating the causes of Familial Hypercholesterolemia, 
Brown and Goldstein characterized the LDLR and elucidated the process 
of receptor-mediated endocytosis (Goldstein & Brown, 1976). For this 
work, they were awarded the Nobel Prize in 1985. They described the 
LDLR as a membrane-spanning glycoprotein that plays a critical role in 
removing LDL and VLDL from the blood (Sudhof, Goldstein, Brown, & 
Russell, 1985). Under low intracellular sterol levels, LDLR gene 
expression is primarily and directly activated by sterol response element-
binding proteins (SREBPs) (Smith, Osborne, Goldstein, & Brown, 1990) 
and secondarily by thyroid hormone (Lopez, Abisambra Socarras, Bedi, & 
Ness, 2007). Translation of the mRNA yields a 120 kDa protein that is 
further post-translationally modified in the Golgi apparatus into a mature, 
160 kDa protein (Tolleshaug, Goldstein, Schneider, & Brown, 1982; 
Yamamoto, et al., 1984). It has been classified as having five regions: an 
N-terminal ligand-binding domain (LBD) (Sudhof, Goldstein, et al., 1985; 
Sudhof, Russell, et al., 1985), an epidermal growth factor precursor 
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homology domain (Davis, Goldstein, et al., 1987; Sudhof, Russell, et al., 
1985), an O-linked polysaccharide domain (Davis, et al., 1986) where the 
protein is post-translationally modified, a membrane-spanning domain 
(Goldstein, Brown, Anderson, Russell, & Schneider, 1985; Lehrman, 
Russell, Goldstein, & Brown, 1987; Lehrman, et al., 1985), and a C-
terminal cytoplasmic domain (Goldstein, et al., 1985). Upon maturation, 
the LDLR is transported to the cell membrane as a clathrin-coated pit 
vesicle (Davis, van Driel, Russell, Brown, & Goldstein, 1987). On the 
membrane, the LBD is exposed to bind and internalize LDL or VLDL, 
mediated by apoB or apoE binding to LDLR, respectively. Once inside the 
cell, the LDLR-ligand-containing vesicle undergoes acidification by proton 
pumps (M. S. Brown & Goldstein, 1986), leading to uncoupling of the 
receptor-ligand complex. At this point, the LDL or VLDL-cholesterol 
undergoes further processing to be readily available for the cell’s 
requirements. Meanwhile, the LDLR can be either recycled or degraded. 
The latter case occurs in a poorly understood process that involves the 
proprotein convertase subtilisin/kexin type 9 or neural apoptosis-
regulated converstase-1 (PCSK9/NARC1), the main regulator of LDLR 
turnover (Maxwell & Breslow, 2004; Maxwell, Fisher, & Breslow, 2005; 
Park, Moon, & Horton, 2004). This property was elucidated by 
characterizing the physiological implications of mutations leading to gain 
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(Abifadel, et al., 2003; Allard, et al., 2005; Cameron, et al., 2008; S. N. 
Chen, et al., 2005; Leren, 2004; Miyake, et al., 2008; Scartezini, et al., 
2007; Sun, et al., 2005; Timms, et al., 2004) and loss of PCSK9 function 
(Abboud, et al., 2007; Berge, Ose, & Leren, 2006; Cameron, et al., 2008; 
Cohen, et al., 2005; Fasano, et al., 2007; Miyake, et al., 2008; 
Scartezini, et al., 2007; Zhao, et al., 2006), which result in LDL-induced 
hypercholesterolemia and hypocholesterolemia, respectively.  
 
Linkage analyses were based on the fact that the LDLR gene locus 
and a region associated with high frequency of AD risk share a common 
location on chromosome 19 (Blacker, et al., 2003; Wijsman, et al., 
2004). Furthermore, this peak of risk for AD onset is independent of the 
risk imparted by the apoE gene (Wijsman, et al., 2004). Consequent 
attempts to characterize linkage of LDLR and AD onset yielded at least 
ten, case-control association studies and one family-based study (Cheng, 
et al., 2005; Corder, et al., 2006; Gopalraj, et al., 2005; Lamsa, et al., 
2008; Lendon, et al., 1997; H. Li, et al., 2008; Papassotiropoulos, et al., 
2005; Retz, et al., 2001; Rodriguez, et al., 2006; Scacchi, et al., 2001; 
Zou, et al., 2008). Of particular interest were polymorphisms contained in 
exons 8, 10, 13, and 15, as they had been proposed to have associations 
with risk of AD onset (Cheng, et al., 2005; Gopalraj, et al., 2005; Retz, et 
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al., 2001). The overall conclusion of these studies is not yet clear.  
 
Other conflicting reports investigating LDLR’s participation in AD 
have taken place at the biological level (Cao, Fukuchi, Wan, Kim, & Li, 
2006; Fryer, et al., 2005; Thirumangalakudi, et al., 2008). The purpose 
for these studies was to investigate whether elimination of LDLR 
expression would affect the AD pathology in mouse models of the 
disease. To this end, Fryer et. al. and Cao et. al. crossed the LDLR-/- 
mouse with AD mouse models: the PDAPP and Tg2576, respectively. Both 
groups agree that LDLR is the main regulator of apoE in CNS as they 
observed a significant increase in apoE levels in the CNS of their 
respective mice. However, Fryer et. al. did not see changes in the 
Alzheimer’s  pathology. On the contrary, Cao et. al. report a mild yet 
significant increase in plaque deposition; furthermore, this study also 
reported that the mice performed poorly on a battery of cognitive tests.  
 
Dietary cholesterol modulates the rate at which APP is processed 
into Aβ. Studies using animals fed high cholesterol diets revealed an 
increase in amyloid plaque formation in rabbits and in transgenic mouse 
models of AD (Howland, et al., 1998; Shie, et al., 2002; Sparks, et al., 
1994); moreover, in these mice, the high cholesterol diet also induced 
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cognitive decline (Thirumangalakudi, et al., 2008). In vitro studies 
demonstrated that APP processing is highly dependent upon the 
availability of cellular cholesterol. Cholesterol-depleted rat hippocampal 
primary neurons show reduced APP processing into Aβ (Fassbender, et 
al., 2001; M. Simons, et al., 1998) yet favor the generation of non-
amyloidogenic APP processing by α-secretase (Bodovitz & Klein, 1996; 
Kojro, Gimpl, Lammich, Marz, & Fahrenholz, 2001).  
 
These biochemical studies employed strategies and approaches that 
attempted to elucidate the effects of LDLR on amyloid pathology in AD 
mice. However, the question of whether LDLR is involved in AD 
pathogenesis and/or progression remains unanswered. Consequently, our 
approach was to determine the effects of amyloid pathology on LDLR 
expression and localization.  The results described in chapter 3 show that 
overexpression of APP/Aβ increased LDLR expression and causes it to 
accumulate in the trans-Golgi network (TGN) by affecting microtubule 
organization. The implications are that LDLR function will be impaired. A 
normal response of decreased levels of intracellular cholesterol is 
transcriptional activation of the metabolic pathways leading to increased 
cholesterol import and de novo biosynthesis. Consistent with these 
results is the upregulation of LDLR mRNA as a sign of reduced 
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intracellular cholesterol. These effects could result in dysregulated 
cholesterol metabolism with increased membrane cholesterol, which in 
turn favors Aβ production.   
 
Another implication is that APP/Aβ-induced microtubule damage 
would inherently affect protein trafficking, vesicle transport, and 
cytoskeletal support provided by the microtubule network. Taken 
together, these events may represent components of AD pathogenesis 
and or progression, and thusly merit further study.  
 
 
 
 
 
 
 
 
 
 
 
 
 51 
 
 
 
 
Final Introductory Remarks 
 
The work presented in the following chapters provides further 
insight into the role of LDLR in AD pathogenesis and/or progression. The 
current knowledge of the LDLR and AD relationship is controversial in that 
both population studies and basic research approaches reach conflicting 
results, which grant or remove participation of LDLR in the pathogenic 
process of Alzheimer’s disease. At best, one may conclude that different 
populations harbor specific polymorphisms in the LDLR gene that result in 
changes in cholesterol homeostasis.  
  
The common mouse model for the study of atherosclerosis is the 
LDLR-/- mouse model of hypercholesterolemia (Cao, et al., 2006; Fryer, 
et al., 2005; Thirumangalakudi, et al., 2008). In principle, this mouse 
model is expected to be deprived of LDLR and should therefore facilitate 
the evaluation of LDLR’s downstream effects. These effects were studied 
with a focus on specific interactions with cholesterol levels in serum and 
CNS, cholesterol homeostasis on a high-cholesterol diet, AD pathology, 
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and cognition. The selection of cholesterol and apoE as targets for 
evaluation is appropriate as they are independent risk factors of AD. 
Likewise, the assessment of changes in AD pathogenesis or cognition was 
performed using a mouse model consisting of a cross between the LDLR-
/- and other AD mouse models.  
 
Our first objective was to study the LDLR-/- model to assess 
whether it is a valid model for evaluating the effect of LDLR absence in 
AD. We surmised that defects in the models could result in opposing 
outcomes. In fact, Thirumangalakudi et. al. discuss this problem in their 
report by delineating differences in AD model backgrounds and ages at 
which the mice were evaluated in the studies by Fryer, et. al. and Cao, 
et. al. Nonetheless, they used the LDLR-/- model as a validated 
transgenic vehicle with precluded LDLR production. 
 
Our second objective was focused on characterizing possible 
alterations to the expression and localization of LDLR in AD. Specifically, 
we investigated the effects of overexpressing APP/Aβ in in vivo and in 
vitro models on LDLR expression and localization. While previous studies 
by others evaluated the absence of LDLR in AD models, we sought to 
determine how APP overexpression altered the expression or location of 
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LDLR. 
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UPREGULATION OF A FUNCTIONAL, STRUCTURALLY HOMOLOGOUS 
SPLICE VARIANT OF LOW0DENSITY LIPOPROTEIN RECEPTOR IN  
LDLR-/- AND ALZHEIMER’S DISEASE MICE 
 
 
Abstract 
 
Alzheimer’s disease (AD) is the most prevalent form of age-associated 
dementia. Besides age, the most important risk factor associated with AD 
onset is the inheritance of the ε-4 allele of apolipoprotein E. ApoE is a 
cholesterol carrier that is internalized by neurons primarily via the low-
density lipoprotein receptor (LDLR). We sought to compare 
apoE/cholesterol uptake by LDLR in the brains and livers of non-
transgenic (NTG) and LDLR-/- mice. RT-PCR experiments revealed the 
presence of a LDLR mRNA that lacks exon 4 (LDLRΔ4) in NTG mice and 
that is upregulated LDLR-/- mice. Because LDLR transcription in LDLR-/- 
mice is interrupted by insertion of a neo cassette with an RNA 
cleavage/polyA addition site in this exon, the Δ4 alternative splicing event 
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evidently bypasses the knock-out scheme. Indeed, immunofluorescence 
and immunoblot assays detected a LDLR-like protein in LDLR-/- brain 
whose distribution in the brains of LDLR-/- mice coincides with that of 
LDLR expression in NTG mice. To determine LDLRΔ4 function, 
immunohistochemistry and functional assays were used to show that this 
LDLR-like variant binds and internalizes apoE. Finally, RT-PCR showed 
that the AD, double-transgenic mouse model, PS+/-APP+/-, expresses 
higher levels of LDLRΔ4 in brain than the NTG control. Our findings 
indicate that an assessment of association between LDLR and AD will 
require a new knock-down model that totally eliminates LDLR in brain. 
Similar alternative splicing may interfere with other knock-out mice. 
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Introduction 
 
Apolipoprotein E (apoE) is pivotal for CNS cholesterol distribution 
(Boyles, et al., 1985; Elshourbagy, et al., 1985) and is the main protein 
component of the very low-density lipoprotein (VLDL) particle in the 
blood (Blum, Aron, & Sciacca, 1980; Mackie, Caslake, Packard, & 
Shepherd, 1981). Consequently, alterations in apoE metabolism result in 
a series of lipid-related disorders. The apoE4 isoform, in particular, is 
linked to an increased risk for cardiovascular ailments (Mahley & Huang, 
1999) and neurodegenerative diseases (Arnold, et al., 1997; Corder, et 
al., 1993; Deane, et al., 2008; Hata, Kunugi, Nanko, Fukuda, & 
Kaminaga, 2002; Ma, Yee, Brewer, Das, & Potter, 1994; Pickar, Malhotra, 
Rooney, Breier, & Goldman, 1997; Potter, Wefes, & Nilsson, 2001; 
Saunders, et al., 1993; T. Wisniewski, Castano, Golabek, Vogel, & 
Frangione, 1994).  
 
The main cellular receptor for lipidated apoE is the low-density 
lipoprotein receptor (LDLR) (Fryer, et al., 2005). In contrast to our 
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extensive knowledge of LDLR function and dysfunction in the periphery, 
the role of LDLR in pathogenic pathways pertaining to the CNS is still not 
fully understood (M. S. Brown & Goldstein, 1986). For example, because 
both abnormal cholesterol metabolism and the presence of the apoE4 
isoform of apoE are risk factors for sporadic, late-onset AD, the LDLR 
may play a role as a potential mediator of AD pathology via its interaction 
with apoE (5-13). Recent studies that investigated this relationship based 
on LDLR-/- mice that had been crossed with AD mouse models, reported 
conflicting conclusions (Cao, et al., 2006; Fryer, et al., 2005).  
 
The mouse LDLR gene is composed of 18 exons that code for a 95 
kDa protein (Goldstein, et al., 1985; Yamamoto, et al., 1984). Some of 
these exons undergo alternative splicing, but potential alternative 
functions of the resulting LDLR splice forms are unknown (Tveten, 
Ranheim, Berge, Leren, & Kulseth, 2006; Zou, et al., 2008). The first five 
LDLR exons encode the ligand-binding domain (LBD), which is composed 
of seven, 40-amino acid repeats (R1-R7) (Goldstein, et al., 1985). Each 
repeat is interspersed with six evolutionarily conserved cysteine residues 
(Goldstein, et al., 1985). Site-directed mutagenesis studies showed a 
marked decrease in LDLR binding to apoB by deletion of any repeat 
between R2 and R7 (Esser, Limbird, Brown, Goldstein, & Russell, 1988; 
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Russell, Brown, & Goldstein, 1989). In turn, deletion of R5, which is 
encoded by exon 4, yielded maximal reduction of apoE binding (Russell, 
et al., 1989). These data suggest that the apoE-binding region surrounds 
R5 of the LDLR ligand-binding domain.  
 
 To further investigate the role of LDLR as a potential mediator of AD 
pathology, we analyzed the LDLR expression profile in liver and brain of 
NTG and LDLR-/- mice. Because of the likely importance of the apoE 
binding site in LDLR for the receptor’s involvement in AD, we focused our 
analysis on exon 4. Specifically, we evaluated the ability of LDLR-/- mice 
to express a LDLR splice variant that lacks exon 4, because a LDLRΔ4 
was recently described in humans (Neff, et al., 2003; Tveten, et al., 
2006). Not only would such a splicing event in mice affect LDLR binding 
to apoE, but it would also bypass the knock-out scheme in the LDLR-/- 
mouse, which is based on the interruption of translation by the insertion 
of a neo cassette in exon 4 (Ishibashi, et al., 1993). 
 
We report that LDLRΔ4 is expressed in both brain and liver in NTG 
mice and is upregulated in LDLR-/- mice. Furthermore, the ability of 
LDLRΔ4 to bind apoE is not impaired. Finally, our finding that LDLRΔ4 is 
even more upregulated in a mouse model of AD and can bind and 
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internalize apoE, suggests that LDLR may play an important role in the 
apoE-related aspects of Alzheimer's pathology. These results also indicate 
that while the LDLR-/- mouse is a valuable model for 
hypercholesterolemia studies in the periphery, the presence of an apoE-
binding LDLRΔ4 splice-variant restricts its use for cholesterol research in 
the CNS. 
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Results 
 
LDLRΔ4-variant mRNA is expressed in mouse liver and brain, and is 
upregulated in both organs in LDLR-/- mice. In order to develop an 
animal model for human hypercholesterolemia in which the potential for 
LDLR gene therapy could be studied, Ishibashi et al. designed a LDLR-/- 
mouse by interrupting exon 4 of the LDLR gene with a neo-encoding 
cassette (Ishibashi, et al., 1993). The recombinant LDLR transcript should 
generate a short mRNA that ends in exon 4 because cleavage and 
polyadenylation is under direction of the neo cassette. Consequently, the 
mice expressing this short mRNA fail to express full-length LDLR protein 
in the liver. Physiologically, this LDLR-/- mouse is characterized by a 7.4-
9-fold increase in serum LDL/IDL and a modest increase in VLDL and 
HDL. This hypercholesterolemic phenotype is routinely enhanced by a 
lipid-rich diet. 
 
We sought to determine the relative amount of LDLR and its splice 
variant, LDLRΔ4, in liver and brain of non-transgenic and LDLR-/- mice. 
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Initially, we used an end-point PCR to identify the splice variant in brain 
and liver of the LDLR-/- mice (Fig. 1). Primer A annealed to a sequence in 
exon 3 (70 bp upstream of the 5’ end of exon 4), whereas primer B 
bound to a sequence in exon 5 (35 bp downstream of the 3’ end of exon 
4) (Fig. 1A). The presence or absence of exon 4 (comprising 384-
nucleotides) should change the size of the PCR product from 489 to 105 
bp, respectively. Our data show that in NTG mice, full-length LDLR is 
expressed in hippocampus, cortex, and liver (Fig. 1B). As expected, in 
LDLR-/- mice, we did not detect full-length LDLR with this PCR strategy. 
However, we did amplify a 105 bp product from LDLR-/- hippocampus, 
cortex, and liver. DNA sequencing of the PCR products confirmed that the 
amplified fragments correspond to exon 4-containing and exon 4-lacking 
LDLR mRNAs. 
 
To further confirm and quantitate LDLRΔ4 mRNA expression in NTG 
and LDLR-/- tissues, we utilized quantitative RT-PCR. We designed two 
sets of primer pairs and TaqMan probes that amplify either the exon 4-5 
boundary that is unique to the full-length LDLR or the exon 3-5 junction 
that is exclusive of the LDLRΔ4. Consistent with the end-point PCR 
results, primer pairs that only recognize the exon 4-5 boundary did not 
detect full-length LDLR mRNA in LDLR-/- mice (Fig. 2A). However, this 
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approach detected trace amounts of LDLRΔ4 in NTG tissues (Fig 2B-D, 
and Table 1). Furthermore in LDLR-/- mice, the LDLRΔ4 variant’s mRNA 
was present and significantly upregulated in both brain and liver (Fig. 
2D). In brains of LDLR-/- mice, the upregulated LDLRΔ4 transcript 
amounts to 50% of the hepatic LDLRΔ4 mRNA (Table 1); this is far more 
than the 1:20- brain/liver ratio of full-length LDLR in NTG mice. Keeping 
in mind that in NTG mice the ratio of LDLRΔ4 to LDLR mRNA levels is 
higher in brain (1:20) than in liver (1:221), our results suggest that 
LDLRΔ4 may play a significant role in brain physiology. 
 
 Anti-LDLR antibody detects protein in LDLR-/- mouse brain. We used 
a polyclonal antibody raised against the amino-terminus of the LDLR 
(Ishibashi, et al., 1993) to assess the expression of LDLR in brain and 
liver of LDLR-/- mice. As previously reported (Ishibashi, et al., 1993), we 
did not detect LDLR bands in the livers of LDLR-/- mice (Fig. 3A). 
However, we observed a band corresponding to a smaller LDLR in the 
brains of NTG and LDLR-/- mice (Fig. 3B). The intensity of this band is 
not significantly different between the two genotypes (Fig. 3C). In 
addition, only in NTG brain we observed a smear above the LDLR 
immuno-reactive band, which corresponds in size and heterogeneity to 
glycosylated LDLR from the liver.  
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In order to compare the cellular location and tissue distribution of 
the LDLR-positive signal in LDLR-/- mice and NTG controls, we immuno-
stained brain and liver sections from these mice. As expected, we 
observed a large decrease in the LDLR signal in livers from LDLR-/- mice 
compared to the NTG controls (Fig. 4B & H). In contrast, in the brains of 
NTG and LDLR-/- mice the LDLR immuno-reactivity was equally strong 
(Fig. 4A). This result was similar to the immunoblot results, which 
showed equal signal intensity in the brains of both mice (Fig. 3B). To 
confirm its specificity, the antibody was pre-incubated with a recombinant 
LDLR protein prior to application to the tissue sections. The LDLR-reactive 
signal was proportionally decreased in the brain sections that had been 
incubated with the pre-adsorbed antibody (Fig. 4C). The signal 
distribution across different brain regions was also conserved between 
the LDLR-/- and NTG mice as determined by immuno-staining (Fig. 4D-
G). We further investigated the location of LDLR signal in primary 
neurons from LDLR-/- and NTG mice. In both genotypes, immuno-
staining analysis revealed LDLR signal in vesicle-like structures 
surrounding the soma and in the dendritic and axonal prolongations of 
primary neurons (Fig. 4I).  
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Primary and tertiary structure analysis show similarities between 
LDLR and LDLR∆4. If the LDLRΔ4 expression in brain is to have 
physiological significance, the LDLRΔ4 protein must either retain the 
function of LDLR or acquire a novel function due to the excision of exon 
4. We examined LDLRΔ4’s activity by first comparing its protein structure 
to the structure of the full-length protein and then testing its apoE-
binding capacity. Each of the seven repeats of the LDLR ligand-binding 
domain (LBD) (R1-R7) has six conserved cysteines (Esser, et al., 1988) 
(Fig 5A). Negatively charged residues are located in the carboxy-terminus 
of each repeat, where they participate in ligand binding. ApoE binding 
occurs in the area surrounding R5 (Esser, et al., 1988; Russell, et al., 
1989). Therefore, if LDLRΔ4 is to bind apoE in a similar manner to the 
full-length LDLR, the protein must include features that are similar to the 
region encompassing R5 in the full-length protein. Exon 4 codes for the 
protein sequence of R3-R5 (highlighted in red in fig. 5A). The resulting 
LBD of LDLRΔ4 is thus composed of R1, R2, R6, and R7 (Fig. 5B). 
Consequently, in LDLRΔ4, R2 substitutes for R5 adjacent to R6. 
Interestingly, an amino-acid sequence alignment of R5 with R2 shows 
conservation of negatively charged residues and those that participate in 
calcium coordination (Fig.5C).  Both of these features are required for 
ligand binding (Goldstein, et al., 1985; Yamamoto, et al., 1984).  
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The sequence similarities between R2 and R5 together with R2's 
position in the protein structure, suggested to us that R2 might have the 
capacity to functionally replace R5 in the shortened LDLRΔ4 protein and 
prompted a search for potential common tertiary structures of the apoE-
binding regions of the LDLR and its LDLRΔ4 variant. Since R2/R6 in 
LDLRΔ4 substitutes for R5/R6 in LDLR, we selected combinations of 
double-repeat sequences of the LDLR ligand binding domain that 
correspond to the region encoded by exon 4 (R2/R3, R3/R4, R4/R5, 
R5/R6), and compared their predicted tertiary structures to that of the 
fused double-repeat R2/R6 of LDLRΔ4 using the SWISS-PROT Repository 
(ExPASy). The comparison showed that the double-repeat structure of 
the apoE-binding region of LDLR (R5/R6) and LDLRΔ4 (R2/R6) are very 
similar and completely different from the structures of all other LDLR 
repeat pairs (Fig. 5D).  
 
LDLR-positive signal in LDLR-/- primary neurons binds and 
internalizes glia-derived apoE. Because the double repeat equivalents of 
the LBDs from LDLR (R5/R6) and LDLR∆4 (R2/R6) predicted similar 
structures (Fig. 5C and D), we hypothesized that they may have similar 
functions as well. To investigate if the protein identified in LDLR-/- mice 
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can function like LDLR, we tested its ability to bind glial-derived apoE. 
ApoE was extracted from primary glial cultures and incubated with 
primary neurons from NTG and LDLR-/- mice. Immunohistochemical 
analysis showed that LDLR-/- primary neurons display similar LDLR 
staining as NTG primary neurons (Fig. 6). In addition, apoE binding was 
found to co-localize with the LDLR signal in both types of cells. As a 
negative control, we incubated primary neurons without primary 
antibodies and found no positive staining for either apoE or LDLR/LDLRΔ4 
(data not shown). Furthermore, addition of 1 µM RAP blocked apoE 
binding to NTG and LDLR-/- neurons (Fig. 6). These results indicate that 
the LDLR-immuno-positive protein in LDLR-/- neurons is capable of 
binding and internalizing apoE.  
 
LDLRΔ4 is upregulated in PSAPP mice brains. Because the presence 
of the apoE4 isoform of apoE is a risk factor for sporadic, late-onset AD 
(Corder, et al., 1993; Saunders, et al., 1993), and because LDLR is the 
main apoE receptor in the brain, it is important to investigate the role of 
LDLR and LDLRΔ4 as potential mediators of AD pathology. To this end, 
we quantified hippocampal and cortical mRNA from 11-12 month-old 
PSAPP and NTG control mice. At this age, PSAPP mice are commonly 
cognitively impaired, and amyloid plaques are prevalent in the 
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hippocampus and cortex (Games, et al., 1995). Using RT-PCR we 
detected equal expression of LDLR mRNA in the PSAPP model of AD and 
age-matched NTG control mice (Fig. 7). However, the LDLRΔ4 variant 
mRNA was found to be two-fold overexpressed in the brains of PSAPP 
mice in comparison to the wild type mice (Table 2). Since both LDLR and 
LDLR∆4 can bind and internalize apoE (Fig. 6), the upregulation of the 
LDLR∆4 variant in mouse models of AD suggests that this splice variant 
may play a role in the apoE-related mechanism of Alzheimer's pathology.  
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Discussion 
 
NTG mice express two types of LDLR mRNA: a full-length form and 
a splice variant that is shortened by 384 nucleotides. Both forms are 
expressed in brain and liver and the full-length form is more strongly 
expressed in liver than in brain.  In the brains of wild-type mice, the 
LDLRΔ4 variant amounts to about 5% of the total LDLR. In the brains of 
LDLR-/- mice, LDLRΔ4 mRNA is 653-fold upregulated in comparison to 
wild-type animals.  We also found that primary neurons of these LDLR-/- 
mice are capable of binding and internalizing apoE. Based on the 
upregulation of LDLRΔ4 mRNA, it is likely that the protein identified in 
LDLR-/- mice is LDLRΔ4. The LDLR antibody we utilized for LDLR 
detection recognizes an epitope upstream of the exon 4-encoded 
fragment and thus should recognize both LDLR and LDLRΔ4. Western blot 
analysis for LDLR in mice reveals a range of bands between 95 and 130 
kDa, which represent different states of post-translational modification. 
The LDLR-like protein detected in LDLR-/- brain showed a molecular 
weight of 95 kDa, which corresponds to the lower end of the range of 
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full-length LDLR signal that was identified in NTG brain (Fig 4B). In 
addition, immunohistochemical assays revealed that the LDLR signal in 
LDLR-/- and NTG tissues resembled the intensity observed in western 
blots, and it was similarly distributed across different brain regions.  
 
LDLR is the primary receptor for lipidated-apoE, which in turn is the 
primary lipid carrier in brain. Disruption of the LBD at the apoE-binding 
juncture precludes apoB binding (Esser, et al., 1988; Russell, et al., 
1989) and is expected to reduce apoE’s linkage to the receptor. However, 
apoE-binding properties and structure are conserved between the full-
length LDLR in LDLRΔ4. Furthermore, we found LDLR and lipidated-apoE 
co-localization in primary neurons of NTG and LDLR-/- mice. These data 
suggest that LDLR-/- mice are able to internalize apoE via a LDLR-like 
protein.   
 
In 2005, Fryer et al. and Cao et al. crossed the LDLR-/- mouse with 
different mouse models of Alzheimer’s disease (PDAPP and Tg2576) (Cao, 
et al., 2006; Fryer, et al., 2005). Although the conclusions of the reports 
contradict each other, resulting in an unclear understanding of LDLR’s 
role in AD, they shed light on the characteristics of the LDLR-/- mouse 
regarding LDLRΔ4. For instance, they show that apoE is increased by 
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60% in LDLR-/- cortex and CSF. This result was corroborated by Elder et 
al. (Elder, et al., 2007), who additionally found a decrease in apoE mRNA. 
While this observation may seem paradoxical, it could suggest that total 
apoE-binding is knocked down in LDLR-/- cortex and apoE translation is 
upregulated as a compensatory response. Alternatively, the observation 
may indicate that a higher amount of apoE has been internalized by 
LDLR-/- mouse cells leading to a reduced transcription of the apoE gene.  
 
We found that LDLRΔ4 mRNA is upregulated two-fold in the brains 
of PSAPP mice. Because LDLRΔ4 internalizes apoE, its overexpression 
should lead to increased intra-neuronal apoE. Another way to increase 
apoE is by feeding high-cholesterol diets. Such food induces cognitive 
deficits in NTG mice and promotes amyloid plaque formation in rabbits 
(Sparks, et al., 1994) and APP transgenic mice (Blacker, et al., 2003; 
Refolo, et al., 2000; Shie, et al., 2002). ApoE has previously been shown 
to be a necessary chaperone for the promotion of amyloid plaque 
deposition in AD mice (Ma, et al., 1994; Potter, et al., 2001; T. 
Wisniewski, et al., 1994). As APP processing is proposed to take place 
inside the cell, the intracellular increase in apoE, endogenous or 
imported, will promote oligomerization of Aβ into fibrils, which will then 
be secreted into the extracellular space. Therefore, it seems likely that 
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the augmented amyloid plaque deposition in LDLR-/- mice found by Cao 
et al. (Cao, et al., 2006) is apoE-related, rather than being a mere 
consequence of diminished LDLR. The combination of increased Aβ and 
apoE in the LDLR-/-xTg2576 mice should thus be sufficient to trigger and 
promote increased amyloid plaque deposits and induce cognitive deficits 
by increasing the relative intracellular concentration of these two 
essential amyloid components.  
 
In sum, our results describe an alternative-splicing phenomenon 
that bypasses the knock-out strategy in the LDLR-/- mouse. Despite 
effective use of this model to study the implications of systemic, apoB-
induced hypercholesterolemia, interpretation of apoE-related changes in 
cholesterol metabolism in the CNS is problematic. As a result, we propose 
that a re-interpretation of previous data acquired by the utilization of the 
LDLR-/- mouse for LDLR-mediated apoE metabolism in the brain is 
appropriate.  
 
To our knowledge, the only other example of a related knockout 
escape by alternative splicing was described for the sorLA/R11 knock-out 
mouse during the preparation of this manuscript. The sorLA/LR11 knock-
out mouse also undergoes an identical splice-mediated elusion of the 
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knock-out scheme as we preliminarily reported in the LDLR-/- mice 
(Abisambra, Padmanabhan, Wefes, Neame, & Potter, 2007; Dodson, et 
al., 2008). The results also implicate deletion of exon 4, the site where 
the new RNA cleavage and poly-adenylation site was introduced in the 
sorLA/LR11-/- mouse. At the mRNA and protein level, the authors found 
similar results to ours, implying that this alternative splicing activity may 
be common in the LDLR family of proteins. Together, these results 
support the conclusion that exon skipping must be considered while 
targeting an exon for knock-out mouse generation. More research to 
determine the normal function of splice variants of LDLR and SorLA/LR11 
should prove valuable in determining if these shortened proteins work 
independently or in concert with the cholesterol and apoE metabolism. 
Furthermore, search for other splicing motifs within gene families may 
shed light on unprecedented regulation of the functions of the products of 
such gene families. In the case of LDLR, the exon 4 splice variant may be 
expressed to eliminate ligand competition between apoB and apoE. If so, 
this phenomenon might be a more efficient pathway for apoE 
metabolism. Participation of other LDLR-family members and their splice 
variants in cholesterol regulation remains to be determined. 
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Materials and Methods 
 
Materials: Quantitative-PCR experiments were performed using products 
from Applied Biosystems, which include PCR master mixes, mouse 
GAPDH endogenous control assays, gene expression assays for LDLR 
exon 4-5 boundary (assay ID Mm01151338_m1), and a custom gene 
expression assay for LDLRΔ4 detection. Tissue culture reagents and 
electrophoresis supplies were purchased from Gibco/Invitrogen. 
Recombinant mouse LDLR was purchased from R&D Systems. Protein 
concentrations were determined with BCATM (Pierce) colorimetric assays.  
Antibodies: Rabbit anti-LDLR antiserum was used as primary antibody for 
immunoblots (1:1000) and immunohistochemistry assays (1:100) 
(Ishibashi, et al., 1993; Russell, et al., 1984). Monoclonal mouse anti-
actin (Sigma-Aldrich) and AlexaFluor 488 and 594 (Invitrogen/Molecular 
Probes) antibodies were diluted according to the manufacturer for 
western blot (WB) and immunohistochemistry (IHC) assays, respectively. 
Goat anti-mouse IRDye®800CW and goat anti-rabbit IRDye®680 were 
purchased from LI-COR Biosciences (WB: 1:15,000; IHC: 1:1500). Mouse 
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anti-apoE monoclonal antibody (BD Biosciences LaboratoriesTM) was used 
for WB, IHC, and immuno-purification of lipidated-apoE. This last 
procedure was done with tosyl-activated, magnetic beads (Dynal Biotech) 
according to manufacturer’s specifications and is described below.   
 
Animals: All procedures involving experimentation on animal subjects 
were done in accord with the guidelines set forth by the University of 
South Florida’s Institutional Animal Care and Use Committee (IACUC). 
The LDLR-/- mouse (B6.129S7-Ldlrtm1Her/J) was obtained from The 
Jackson Laboratory (Ishibashi, et al., 1993). Mice with the genotype 
APP+/-, PS1+/- were generated by crossing heterozygous PDGF-
hAPP(V717F) mice [Swiss-Webster X C57BL/6] with PDGF-hPS1(M146L) 
heterozygotes [Swiss-Webster X C57BL/6] as described (Costa, et al., 
2007). Non-transgenic (NTG) control mice for LDLR-/- mice were 
C57BL/6J expressing endogenous LDLR (The Jackson Laboratory). NTG 
control mice for APP+/-, PS1+/- were littermates that lacked both 
transgenes. All mice were genotyped by PCR to confirm the presence or 
absence of LDLR (Ishibashi, et al., 1993; Soriano, Montgomery, Geske, & 
Bradley, 1991), PDGF-hAPP  (Games, et al., 1995), and PDGF-hPS1 
(Duff, et al., 1996).  
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Tissue preparation: Brains and livers were acquired by anesthetizing mice 
with 0.1 mg/g Nembutal followed by transcardial perfusion with 0.9% 
saline solution for 8-12 min at 120 mmHg. Portions of the left, right, and 
median lobe of the mice livers, as well as whole brains were immediately 
removed for processing. Messenger RNA was extracted by homogenizing 
tissues in TRI reagent (Sigma-Aldrich). Only cortices and hippocampi 
were processed for brain mRNA isolation; All liver extracts consisted of 
the same liver portions for each mouse. Microsome protein extracts were 
obtained as previously described (Ness, Sample, Smith, Pendleton, & 
Eichler, 1986), with minor modifications: 0.25M sucrose was prepared 
with protease inhibitors (1 tablet mini-Complete/ 10 ml sucrose, Roche 
Applied Science). Samples were spun once at 30,000 x g for 90 min in a 
fixed-angle rotor. Microsome pellets were resuspended in PBS with 10% 
glycerol and protease inhibitor cocktail (Roche). Brains for 
immunohistochemistry assays were fixed for 24 hrs in 4% para-
formaldehyde. The fixed tissues were cryo-protected in successive 
sucrose gradients as previously described (Nilsson, et al., 2001). Brains 
were frozen on a temperature-controlled freezing stage, coronally 
sectioned (25 µm) on a sliding microtome, and stored in a solution of PBS 
containing 0.02% NaN3 at 4oC.  
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End point RT-PCR and quantitative RT-PCR: Five micrograms of DNase-
treated mRNA were reverse-transcribed with SuperScript® VILOTM cDNA 
Synthesis Kit (Invitrogen) using random hexamers according to the 
manufacturer’s instructions. Endpoint PCR was conducted using primer A 
(sense): 5’– TGCATTCCTGACTCCTGGAGATGT -3’ and Primer B (anti-
sense): 5’ –ACACTGGAATTCATCAGGTCGGCA -3’ (IDT). Thermal cycling 
conditions were 95°C for 5 min, 35 cycles of 95°C for 30 seconds, 56°C 
for 60 seconds, and 72°C for 60 seconds. PCR products were analyzed in 
1.5% TAE-agarose gels stained with ethidium bromide. Gels were 
scanned with the Alpha Imager (Alpha Innotech). Copy-DNA was 
recovered from the bands and sequenced at H. Lee Moffitt Cancer Center 
& Research Institute DNA Sequencing Core. Quantitative RT-PCR was 
performed according to manufacturer. Custom gene-expression assay for 
LDLRΔ4 detection contained a sense primer (5’ –
TGGACAGGTAGACTGTGAAAATGAC -3’), an anti-sense primer (5’ –
CATCTGCACACTGGAATTCATCA- 3’), and a FAM-conjugated, MGBTM probe 
(5’ –AACAAGGCTGTCCGGTGG -3’); the resulting PCR product spans the 
exon 3-5 boundary. Quantitative-PCR reactions were processed in the 
7500 FAST System with its Sequence Detection Software (SDS) from 
Applied Biosystems. 
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Western blots: Unless otherwise indicated, 15 µg and 50 µg (protein) of 
liver and brain microsomes, respectively, were denatured with LDS 
sample buffer according to the Invitrogen protocol. Samples were loaded 
onto 3-8%, 1.0 or 1.5mm Tris-Acetate gels, and run at 80V for 180 min. 
Gels were dry-transferred onto PVDF membranes for 9 min (iBlot, 
Invitrogen). Non-specific protein binding to the membrane was blocked 
by incubating with 5% BSA for 90 min at room temperature. Primary 
antibodies for actin and LDLR were diluted 1:10000, and 1:1000  in 
blocking buffer and incubated overnight at 4°C. Monoclonal mouse anti-
actin antibody and secondary antibody incubations with IR-dyes 
(1:15000) were performed sequentially for 60 min at room temperature. 
Membranes were washed three times for 10 min with PBS and 0.1% 
Tween-20 after incubation with each antibody. Membranes were scanned 
and analyzed with the LI-COR Odyssey and accompanying software. 
 
Immunohistochemistry: Brain sections were mounted onto 
Colorfrost®/Plus slides (Fisher Scientific). Non-specific binding was 
blocked in NGS (10% normal goat serum, 0.2% Triton X-100, and 0.02% 
NaN3 in Tris-buffered saline (TBS)) for 120 min at room temperature. 
Primary antibodies were incubated overnight at 4°C in 10% NGS. After 
four 5 min washes in TBS, slides were incubated with secondary 
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antibodies (IR-dyes or AlexaFluor) in 10% NGS for 60 min at room 
temperature and washed in TBS. Slides were stained with Hoechst 
(1µg/ml in PBS) for 2 minutes to reveal cellular nuclei and mounted using 
GelMount (Fisher Scientific). Staining was analyzed with the Zeiss 
AxioImager.Z1 and AxioVision software. 
 
ApoE binding studies: Primary glial cells were isolated from E18 fetuses of 
NTG mice (Padmanabhan, Levy, Dickson, & Potter, 2006) and cultured in 
75 cm2 flasks coated with poly-lysine D (50 µg/ml). The tissue culture 
supernatant from these cells was used for purification of lipidated-apoE.  
The ApoE purification protocol (Fagan, et al., 1999) was modified by 
immuno-purifying lipidated apoE with an anti-apoE antibody conjugated 
to magnetic beads. Conjugation, purification, and elution were done 
according to manufacturer’s specifications (company). Cortical and 
hippocampal neurons were isolated from E18 fetuses of LDLR-/- and NTG 
controls as described (Padmanabhan, et al., 2006). Primary neurons were 
grown for one week on poly-L-lysine-coated 8-chamber slides in 
neurobasal media with B27 supplement and then treated with 0.5 µM 
lipidated apoE for 60 min at 37°C. Control cells were treated with 0.5 µM 
lipidated apoE that had been pre-incubated overnight at 37°C with 1 µM 
receptor-associated protein (RAP), a dose that effectively blocks ligand 
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binding to LDLR family members (Fryer, et al., 2005; Medh, et al., 1995). 
Cells were washed in PBS and then fixed in 4% para-formaldehyde for 10 
min. Slides were immuno-stained for LDLR and apoE as described above.  
 
Protein modeling: Three-dimensional images were created in the 
alignment mode functionality of the SWISS-MODEL Repository from 
ExPASy. Sequences spanning different two-repeat combinations of the 
LDLR ligand-binding domain were aligned with the LDLR tertiary structure 
in the database.  
 
Statistical analyses: All data reported were obtained from independent 
experiments repeated at least three times. Data were plotted as ±SE of 
the mean. P-values were obtained from paired t-test analyses. 
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Figures 
 
FIGURE 1. LDLRΔ4-variant mRNA is expressed in brain and liver 
of LDLR-/- mice. 
End-point PCR was used to identify LDLRΔ4 transcripts. (A) Primers A and 
B were designed to anneal 70 bp upstream and 35bp downstream of exon 
4, respectively. (B) Amplification of cDNA from NTG and LDLR-/- 
hippocampus, cortex, and liver gave products corresponding to full-length 
LDLR (489 bp) or LDLR lacking exon 4 (105 bp).  
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FIGURE 2. LDLRΔ4-variant mRNA is expressed in brain and liver 
of NTG mice and upregulated in brain and liver of LDLR-/- mice. 
Real-time quantitative RT-PCR was used to detect LDLR (A) and LDLRΔ4 
(B) mRNA in brain and liver of NTG and LDLR-/- mice. Primer and probe 
sets were specifically designed to amplify the exon 4-5 and 3-5 
boundaries of cDNA from brain and liver samples. Relative quantitation of 
LDLRΔ4 and LDLR were obtained from three independent experiments 
using samples from NTG mice (n=5). Trace amounts of LDLRΔ4 signal 
were detected above background in brain (C) and liver (D) of NTG mice. 
LDLRΔ4 signal between brain and liver of LDLR-/- was p > 0.05. 
Student’s t-tests were performed using data from experiments done in 
triplicate. ND: not detectable. P-values in the graphs correspond to the 
statistical difference between the conditions indicated within the brackets.  
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TABLE 1. LDLRΔ4-variant mRNA is upregulated in LDLR-/- mice. 
Summary of RT-PCR data from figures 1 and 2. 
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FIGURE 3. LDLR-positive protein is present in LDLR-/- brain, but 
not liver. 
Western blots for LDLR in liver (A) and brain (B) using the anti-LDLR 
antibody. Gels were loaded with equal amounts of microsomal proteins. 
Actin detection was used as a loading control. (C) Quantitation of the 
relative intensity of the LDLR-positive signal in NTG and LDLR-/- brain 
samples (n=5; P=0.63). NL: NTG liver; -/-L: LDLR-/- liver. 
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FIGURE 4. LDLR signal is present in brain and primary neurons of 
LDLR-/- and NTG mice with similar intensity and distribution. 
Brain (A) and liver (B) sections of NTG and LDLR-/- mice were immuno-
stained with anti-LDLR antibody, detected with IR Dye 680 goat anti-
rabbit secondary and scanned on the Odyssey Imager. Signal detection 
was proportionally inhibited with incubation of the primary antibody with 
increasing amounts of rmLDLR (C). (D-H) Sagittal sections of NTG and 
LDLR-/- brain and liver were immuno-stained with anti-LDLR antibody. 
Representative images of medial cortex (D), hippocampus (E), ventricle 
(F), cerebellum (G), and liver (H) are shown. The negative control 
samples correspond to staining without primary antibody. (I) Primary 
neuronal cultures from NTG and LDLR-/- mice were immuno-stained as 
described for panels D-H. rmLDLR: recombinant-mouse LDLR protein. 
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FIGURE 5. ApoE binding in LDLR-/- primary neurons via LDLR 
protein is conserved. 
(A) The seven repeats of the LDLR LBD are aligned to show distribution of 
the six cysteine-containing regions in each repeat. The sequence coded 
by exon 4 is highlighted in red. (B) The resulting LBD of LDLRΔ4 contains 
repeats 1, 2, 6, and 7 of the full-length LDLR. R5 and R2 are the repeats 
that flank upstream of R6 in the LDLR and LDLRΔ4 LBD, respectively. (C) 
Residues participating in ligand binding (*) and calcium coordination (#) 
are shown within the boxes. (D) Schematics derived from ExPASy 
indicating the tertiary structures of coupled repeats in the LDLR LBD. (i-
iv) Tertiary structures of the sequences spanning repeats 2 and 3 (i), 3 
and 4 (ii), 4 and 5 (iii), and 5 and 6 (iv) of the LDLR. The last image (v) 
corresponds to the sequences of repeat 2 and 6, which is the resulting 
apoE-binding region of LDLRΔ4. 
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FIGURE 6. Glia-derived apoE co-localizes with LDLR protein on the 
plasma membrane and cytoplasm of NTG and LDLR-/- primary 
neurons. 
Primary neurons from NTG and LDLR-/- mice were incubated with glia-
derived apoE. Cells were fixed and immuno-stained for LDLR (red) and 
apoE (green). The merged image (yellow) shows potential  Hoechst 
staining was used as a nuclear marker.  
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FIGURE 7. LDLRΔ4-variant mRNA expression is upregulated in the 
PSAPP mouse brain. 
LDLR and LDLRΔ4 mRNA expression in NTG and PSAPP brain tissue was 
detected by quantitative RT-PCR. (n=5; P-value for LDLRΔ4 is 0.01). Mice 
were 11-12 months old, and experiments were done in triplicate.  
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TABLE 2. Increased LDLRΔ4 mRNA expression in PSAPP mice. 
Summary of RT-PCR data from figure 7. 
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LDLR EXPRESSION AND LOCALIZATION ARE ALTERED IN MOUSE AND 
HUMAN CELL CULTURE MODELS OF ALZHEIMER’S DISEASE 
 
 
Abstract 
 
Background: Alzheimer’s disease (AD) is a chronic neurodegenerative 
disorder and the most common form of dementia. The major molecular 
risk factor for late-onset AD is expression of the ε-4 allele of 
apolipoprotein E (apoE), the major cholesterol transporter in the brain. 
The low-density lipoprotein receptor (LDLR) has the highest affinity for 
apoE and plays an important role in brain cholesterol metabolism.  
Methodology/Principal Findings: Using RT-PCR and western blotting 
techniques we found that over-expression of APP caused increases in 
both LDLR mRNA and protein levels in APP transfected H4 neuroglioma 
cells compared to H4 controls. Furthermore, immunohistochemical 
experiments showed aberrant localization of LDLR in both H4-APP 
neuroglioma cells and in the PSAPP transgenic mouse model of AD. 
Finally, these changes were paralleled by and likely the result of a 
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disruption of the microtubule-organizing center and associated 
microtubule network, as evidenced by immunofluorescent staining of both 
γ- and α-tubulin.  
Conclusions/Significance: These data suggest that increased APP alters 
microtubule function leading to alterations in LDLR location. Consequent 
deleterious effects on apoE uptake and function will have implications for 
AD pathogenesis and/or progression. 
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Introduction 
 
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder 
and the most common form of dementia. Currently, almost 50% of the 
population over 85 years of age suffers from AD. Onset of the disease 
after age 65 is described as late-onset or sporadic AD, which accounts for 
over 95% of the cases and has an idiopathic etiology. Extracellular β-
amyloid deposits in the cores of neuronal (senile) plaques and in vessel 
walls, intraneuronal neurofibrillary tangles, and neuroinflammation 
characterize the disease’s pathology resulting in accelerated neuron loss 
and dementia (Glenner & Wong, 1984). Amyloid deposits are the result of 
abnormal processing of the amyloid precursor protein (APP) by two 
enzymes: β- and γ-secretase. Mutations in the two presenilin (PS) genes 
encoding the catalytic core of γ-secretase as well as mutations in the APP 
gene lead to increases or alterations in Aβ, a 38-42 amino acid peptide 
and the seed for, and major component of amyloid pathology. The 
particular structure of Aβ42, which is the most pathogenic form, confers 
the ability to self-aggregate, oligomerize, and, dependent on the 
presence apolipoprotein E (apoE), to polymerize into amyloid filaments 
 143 
 
(Mahley, et al., 2006; Potter, et al., 2001; Strittmatter, et al., 1993). 
 
The ε-4 isoform of apoE is the strongest molecular risk factor for 
the development of AD. About 60-80% of AD patients have at least one 
copy of apoE4 (Mahley, et al., 2006; Saunders, et al., 1993; Strittmatter, 
et al., 1993) and the risk for AD is increased in an ε-4 allele dose-
dependent manner (Corder, et al., 1993). ApoE is a 34 kDa, 299-amino 
acid glycoprotein and is the chief cholesterol transporter in the central 
nervous system (CNS). It’s gene, located on chromosome 19q13, may 
code for any homozygote or heterozygote combination of three common 
isoforms, apoE2, apoE3, and apoE4 (Havel & Kane, 1973; Zannis, et al., 
1981). In the CNS, apoE-cholesterol is principally made in astrocytes and 
exported to neurons (Boyles, et al., 1985; Elshourbagy, et al., 1985); 
however, neurons can also produce apoE-cholesterol during stress (Q. 
Xu, et al., 2006). Despite the presence of several receptors that are 
capable of internalizing apoE such as low-density lipoprotein receptor 
(LDLR), LDLR-related protein (LRP), apoER2, and VLDLR, in neurons apoE 
is mostly imported via the LDLR (Innerarity & Mahley, 1978; Innerarity, 
et al., 1979; Mahley, 1988; Mahley & Rall, 2000).  
 
LDLR is a membrane-spanning glycoprotein that plays a critical role 
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in removing LDL and VLDL from the blood (Goldstein & Brown, 1976; 
Sudhof, Goldstein, et al., 1985). Under low intracellular sterol levels, 
LDLR gene expression is primarily and directly activated by sterol 
response element-binding proteins (SREBPs) (Smith, et al., 1990) and 
secondarily by thyroid hormone (Lopez, et al., 2007). The translation of 
LDLR mRNA yields a 120 kDa protein that is post-translationally modified 
in the Golgi apparatus into the mature, 160 kDa LDLR (Tolleshaug, et al., 
1982; Yamamoto, et al., 1984). The mature receptor can be divided into 
five regions: the N-terminal ligand-binding domain (Sudhof, Goldstein, et 
al., 1985; Sudhof, Russell, et al., 1985), the epidermal growth factor 
precursor homology domain (Davis, Goldstein, et al., 1987; Sudhof, 
Russell, et al., 1985), the O-linked polysaccharide domain (Davis, et al., 
1986) where the protein is post-translationally modified, the membrane-
spanning domain (Goldstein, et al., 1985; Lehrman, et al., 1987; 
Lehrman, et al., 1985), and the C-terminal cytoplasmic domain 
(Goldstein, et al., 1985). Upon maturation, LDLR is transported to the cell 
membrane via a clathrin-coated pit vesicle (Davis, van Driel, et al., 
1987). On the membrane, the ligand-binding domain is exposed 
extracellularly to associate and internalize LDL or VLDL, mediated by 
apoB or apoE, respectively. Once inside the cell, LDLR-ligand-containing 
vesicles are acidified by proton pumps (M. S. Brown & Goldstein, 1986), 
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leading to uncoupling of the receptor-ligand complex. At this point, the 
LDL or VLDL-cholesterol undergoes further processing to be readily 
available for the cell’s requirements.  
 
Several groups identified a potential contribution of LDLR to AD and 
investigated potential links, for example by crossing AD transgenic mice 
with the LDLR-/- mouse model of hypercholesterolemia to investigate the 
effects of LDLR deficiency (Blacker, et al., 2003; Cheng, et al., 2005; 
Corder, et al., 2006; Gopalraj, et al., 2005; Lamsa, et al., 2008; H. Li, et 
al., 2008; Papassotiropoulos, et al., 2005; Retz, et al., 2001; Rodriguez, 
et al., 2006; Scacchi, et al., 2001; Wijsman, et al., 2004). Some 
apparently opposing results were obtained. Here we investigate the 
effects of APP over-expression on the expression and localization of LDLR 
to identify possible changes that could result in an altered apoE 
metabolism. We report that over-expression of APP in a human 
neuroglioma cell line increased the amounts of LDLR mRNA and protein, 
and the receptor accumulated in the perinuclear region of the APP-
expressing cells. This altered localization was specific to LDLR and could 
not be seen for LRP. Furthermore, in comparing NTG with PSAPP and 
APP-/- transgenic mouse models, we found that LDLR protein levels were 
directly proportional to the amount of APP. Immunohistochemical analysis 
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of α- and γ-tubulin suggest that alterations in LDLR are rooted in an APP-
mediated disturbance of the centrosome and microtubules, preventing 
proper transport of LDLR to the plasma membrane.  
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Results 
 
Initially, we sought to determine changes in the mRNA and protein 
levels of LDLR in human neuroglioma cells that were stably transfected 
with human wild-type APP (H4-APP) and used their non-transfected H4 
counterpart as controls. H4-APP cells express about 12 times more APP 
than non-transfected controls and it is distributed throughout the whole 
cell (Supplemental Figure S1). RT-PCR experiments with H4 and H4-APP 
cells demonstrated a 3-fold increase in LDLR mRNA in H4-APP cells 
compared to H4 controls (Figure 1A). This result was paralleled at the 
protein level as evidenced by western blot analysis (Figure 1B). 
Quantification of the immunoblots showed a 4-fold increase in LDLR 
protein in H4-APP cells compared to H4 controls (Figure 1C).  
 
Next, we performed immunofluorescence imaging on H4 and H4-
APP cells to determine changes in LDLR localization. In order to assess 
whether potential APP-induced alterations were specific to LDLR, we 
immunostained for LDLR and another member of the LDLR family, LRP 
(LDLR-related protein-1) (Figure 2A). Images of H4 and H4-APP cells 
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without primary antibody incubation are shown as a negative control of 
the assay (Figure 2A). While we did not observe significant changes in 
the distribution of LRP, we found that in H4-APP cells, LDLR had become 
densely concentrated in the perinuclear region (indicated by the 
arrowheads in panels 2A and 2B). Compared to LDLR localization, the LRP 
signal was concentrated in a perinuclear density in both H4 and H4-APP 
cells. At closer inspection (Figure 2B), we confirmed that in H4 control 
cells, LDLR is homogeneously distributed, whereas in H4-APP cells, LDLR 
appears to converge to form a dense perinuclear core. To quantifify this 
effect, we defined cells displaying a dense LDLR-positive focus as cells 
containing a signal that was three standard deviations above the 
background and with at least 1000 pixels2. By this criterion, 59% of H4-
APP versus 10% of H4 cells had LDLR accumulated in the perinuclear 
zone of the cells. (Figure 2C; *p = 0.001). In contrast, 72% of H4-APP 
cells and 66% of H4 cells displayed the dense perinuclear signal for LRP, 
not indicating any significant change (Figure 2D; p = 0.56).  
 
It seems reasonable that if LDLR becomes highly concentrated in a 
single perinuclear core, then there may be a relative deficit of LDLR in its 
normal, physiologically relevant location on the plasma membrane.  We 
therefore examined H4 and H4-APP cells with the LDLR antibody as 
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above, but leaving out the permeabilization step so as to only visualize 
cell-surface LDLR. H4-APP cells exhibited a 32% significant reduction of 
plasma membrane-associated LDLR (Figure 3A, 3B, and 3C). This result 
indicated that there was likely a concomitant reduction in LDLR function, 
despite the compensatory upregulation of LDLR mRNA and protein shown 
in Figure 1. 
 
AD pathology is initiated and maintained when the APP protein 
becomes proteolytically cleaved to generate various forms of the Aβ 
peptide, the 1-42 amino acid version being one of the most pathogenic.  
In order to assess the general relevance of the redistribution of the LDLR 
in H4-APP cells, we repeated the experiment using cultured mouse 
cortical neurons from normal mice and exposing them to 1uM of either 
Aβ40 or Aβ42 for 48 hours; as a reference, we also treated and 
immunostained a set of neurons with a peptide consisting of scrambled 
amino acids of the Aβ42 peptide (Figure 4A and 4B). Similar to the H4-APP 
cells, the Aβ40- and Aβ42-treated cortical neurons had 23%  (*p < 0.05) 
and 13% (**p < 0.01) less surface LDLR compared to Aβ42 scrambled 
peptide-treated cells (Figure 4C). The amount of surface LDLR was also 
significantly decreased in Aβ40-treated compared to Aβ42-treated cells 
(10%; *p < 0.05). 
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Thus far we have shown that the upregulated LDLR protein in H4-
APP cells cannot be accounted for on their cell membrane. To identify the 
localization of the LDLR aggregate, we co-stained LDLR with organelle 
markers for the Golgi apparatus (Figure 5A and 5B), lysosomes (Figure 
5C and 5D), endoplasmic reticulum (Figure 5E and 5F), and early 
endosomes (Figure 5G and 5H). We found that in H4-APP cells, LDLR 
signal co-localized in the Golgi apparatus and lysosomes, or the trans-
Golgi network. In contrast, LDLR signal in the ER or endosomes was not 
particular to either H4 or H4-APP cells.  
 
We next sought to reproduce the APP-induced LDLR over-
expression and mis-localization in a physiologically relevant experimental 
system—an in vivo model of AD. We chose PS1+/-APP+/- (PSAPP) mice 
at 10 months of age when their brains are burdened with amyloid, 
homogenized brain tissue from the PSAPP mice and age-matched non-
transgenic (NTG) controls and performed western blot analysis for LDLR. 
We observed a modest, yet significant increase of LDLR in PSAPP mice 
compared to controls (Figure 6A and 6B; 20% increase with *p = 0.05). 
The same experiment served to confirm that the PSAPP mice 
overexpressed APP (Figure 6A). In order to further investigate whether 
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the LDLR protein levels are influenced by APP expression, we performed 
western blots for LDLR in 10-month old APP-/- mice. Interestingly, we 
found that LDLR was decreased by 55% in these mice compared to age-
matched controls (Figure 6C and 6D; *p = 0.04). These experiments 
indicate that LDLR expression directly correlates with APP expression. 
 
To determine if changes in LDLR expression are paralleled by 
changes in its localization in PSAPP mice, we performed 
immunohistochemistry on brain tissue sections of PSAPP mice of 10 
months and age-matched controls. We detected an increase in the LDLR 
signal in the hippocampus of PSAPP mice, a region that is particularly 
affected by the amyloid pathology. This effect was the strongest in the 
CA3 region of the hippocampus (Figure 7A). At higher magnification, we 
found that cells surrounding the neuronal layer of the hippocampus in 
PSAPP tissues also showed a dense accumulation of LDLR similar to that 
observed in H4-APP cells (arrowhead in PSAPP hippocampal cell of figure 
7A), whereas the NTG counterpart lacked that same signal concentration 
(Figure 7A). After quantification of the LDLR signal normalized to the 
amount of DAPI signal in each field, we calculated a 30% increase (*p = 
0.04) in LDLR in the hippocampi of PSAPP mice compared to NTG controls 
(Figure 7B).  
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The centrosome, or microtubule-organizing center (MTOC), is 
responsible for the nucleation step preceding the polymerization of 
microtubules and maintains the structure of the microtubule network. It 
was previously reported that PS1 and APP bind to the centrosome (J. Li, 
Xu, Zhou, Ma, & Potter, 1997; Nizzari, et al., 2007). We therefore 
reasoned that the mechanism behind the changes in localization and 
expression levels of LDLR mRNA and protein could be based on an APP-
mediated alteration of the microtubule-trafficking system. To address this 
hypothesis, we performed immunohistochemistry in H4 and H4-APP cells 
targeting γ-tubulin as a marker of the MTOC. While we observed 
condensed staining of γ-tubulin in H4 cells, H4-APP cells showed a diffuse, 
non-nuclear pattern of γ-tubulin signal (Figure 8A and 8B) where 0.64% 
of the γ-tubulin signal was dispersed in H4-APP cell. In contrast, 0.72% 
percent of the γ-tubulin signal was diffuse in the H4 cells; this was a 
modest change (0.08%), yet it was significantly different (*p = 0.01; 
Figure 8C).  
 
Finally, to address the relationship between APP over-expression 
and alterations to the mature microtubule-trafficking network, we 
performed immunofluorescent staining of H4 and H4-APP cells targeting 
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α-tubulin as an indicator of microtubule localization. We found that only 
82% of the alpha-tubulin signal in H4-APP cells was diffuse, while H4 cells 
had 87% of the total α-tubulin signal spread throughout the cell (Figure 
9A and 9B). Like in the γ-tubulin staining experiment, this was a modest 
but significant change in signal distribution (5%; *p = 0.04) between the 
transgenic and non-transgenic (Figure 9C).  
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Discussion 
 
 Characterization of apoE metabolism in the brain is of critical 
importance for the development of potential therapeutic targets for AD. 
Because apoE is the principal ligand for LDLR, alterations to LDLR 
trafficking are likely to impact AD pathology as well. As the main 
cholesterol transporter in the CNS, apoE is produced by glia and delivers 
cholesterol cargo to neurons by receptor-mediated endocytosis via LDLR. 
In order for apoE-cholesterol to enter the cell, LDLR must be localized to 
the plasma membrane. Our findings indicate that in H4-APP cells and 
primary neurons treated with Aβ, this localization is altered in that there 
is a significant decrease in the amount of cell surface LDLR (Figure 3 and 
4). As, transcriptional activation of the LDLR gene is normally induced by 
a system that is sensitive to low levels of intracellular sterols (Smith, et 
al., 1990), it seems likely that the upregulation of LDLR (Figure 1) 
indicates that the H4-APP cells are cholesterol starved due to non-
functional localization of LDLR.  
 
Dietary and endogenous biosynthesis of cholesterol modulates the 
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rate at which APP is processed into Aβ. Studies using animals fed high 
cholesterol diets revealed an increase in amyloid plaque formation in 
rabbits and in transgenic mouse models of AD (Howland, et al., 1998; 
Shie, et al., 2002; Sparks, et al., 1994); moreover, in these mice, the 
high cholesterol diet induced cognitive decline (Thirumangalakudi, et al., 
2008). In vitro studies show that imbalances in cellular cholesterol may 
favor APP cleavage by either α- or γ-secretase. Conversely, cholesterol-
depleted rat hippocampal primary neurons show reduced APP processing 
into Aβ (Fassbender, et al., 2001; M. Simons, et al., 1998) and favor the 
generation of non-amyloidogenic APP processing by α-secretase to yield 
the soluble, non-pathogenic protein sAPPα (Bodovitz & Klein, 1996; 
Kojro, et al., 2001). In contrast, γ-secretase processing is favored when 
APP is located in the lipid raft; the result is formation of toxic Aβ peptide. 
Thus, the amount and distribution of cellular cholesterol is essential for 
the formation of lipid rafts, and therefore the localization and processing 
of APP. This connection might also mean that if the observed increased 
expression of LDLR in apparent compensation for incorrect localization 
induced by APP overshoots, then more apoE-cholesterol could be 
imported, leading to more APP processing to Aβ in an accelerating 
pathogenic cycle.  
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Our experiments on PSAPP mice show that LDLR and APP protein 
levels are directly proportional (Figure 3). These results together with 
those obtained with the H4 and H4-APP cell models suggest that APP 
over-expression affects the MTOC such that LDLR transport to the cell 
membrane is significantly abrogated. Consequently, net cholesterol 
import into the cell is decreased, leading to upregulation of LDLR 
transcription and protein levels. It was previously shown that APP and 
PS1 bind to the centrosome (J. Li, et al., 1997; Nizzari, et al., 2007). As a 
result, the centrosome’s nucleation function for microtubule formation 
may be disrupted by association with excess levels of APP or Aβ in our 
over-expression models or by mutations of the APP gene. This in turn 
may have widespread detrimental effects for the entire microtubule 
trafficking system. Our results provide evidence that trafficking of other 
proteins, organelles, or vesicles in the cell may also be disturbed, 
although this cannot be true for all proteins as LRP localization was 
unchanged in the H4-APP cells. (Figure 2A).  
 
Over the past 15 years, a considerable amount of effort has been 
dedicated to characterize the potential participation of LDLR in AD 
pathology. This interest is based on data procured from linkage analyses 
of AD risk and the LDLR gene, preliminary data from population and case-
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control studies, and the importance of LDLR function in the regulation of 
cholesterol homeostasis via apoE metabolism, whose e4 allele is the most 
important risk factor for ‘sporadic’ AD besides age. Linkage analyses were 
based on the fact that the LDLR gene locus and a region associated with 
high frequency of AD risk share a common location on chromosome 19 
(Blacker, et al., 2003; Wijsman, et al., 2004). Furthermore, this peak of 
risk for AD onset is independent of the risk imparted by the nearby apoE4 
gene (Wijsman, et al., 2004). Consequent attempts to characterize 
linkage of LDLR and AD onset yielded at least ten, case-control 
association studies and one family-based study (Cheng, et al., 2005; 
Corder, et al., 2006; Gopalraj, et al., 2005; Lamsa, et al., 2008; Lendon, 
et al., 1997; H. Li, et al., 2008; Papassotiropoulos, et al., 2005; Retz, et 
al., 2001; Rodriguez, et al., 2006; Scacchi, et al., 2001; Zou, et al., 
2008). Of particular interest were polymorphisms contained in exons 8, 
10, 13, and 15, as they had been proposed to have associations with risk 
of AD onset (Cheng, et al., 2005; Gopalraj, et al., 2005; Retz, et al., 
2001). The overall conclusion of these studies is, however, still 
developing. 
 
Other conflicting reports have investigated LDLR’s participation in 
AD at the molecular level (Cao, et al., 2006; Fryer, et al., 2005; 
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Thirumangalakudi, et al., 2008). The objective of these studies was to 
study whether elimination of LDLR expression would affect the pathology 
in AD mice. To this end Fryer et. al. (Fryer, et al., 2005) and Cao et. al. 
(Cao, et al., 2006) crossed the LDLR-/- mouse with mouse models of AD: 
the PDAPP and Tg2576, respectively. Both groups agreed that LDLR is the 
main regulator of apoE in CNS as they observed a significant increase in 
apoE levels in the CNS of their mice. However, Fryer et. al. did not 
observe changes in pathology, whereas Cao et. al. reported a mild yet 
significant increase in plaque deposition. Furthermore, this latter study 
also reported that the mice performed poorly on a battery of cognitive 
tests. The question of whether LDLR is involved in AD pathogenesis 
and/or progression remains unanswered.  
 
In contrast to the investigations of the role of LDLR in AD, our 
approach was to determine instead the effects of amyloid pathology on 
LDLR metabolism. We describe in this report that APP/Aβ over-expression 
causes alterations to LDLR that may be explained by an APP/Aβ-mediated 
effect on the microtubule trafficking system. In H4-APP cells, a human 
neuroglioma cell line stably over-expressing human wild-type APP, LDLR 
mRNA and protein levels are increased. In these conditions, H4-APP had 
LDLR aggregated in the trans-Golgi network, which precluded its 
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trafficking to the cell membrane. Furthermore, Aβ treatment also caused 
aggregation of the LDLR signal. Concomitantly, the PSAPP mouse model 
of AD, which over-expresses the full-length human APP containing the 
V717F mutation, also shows aberrant distribution and a mild, yet 
significant increase in LDLR protein. The experiments suggest that a likely 
explanation for these phenomena is that H4-APP cells have changes in 
the localization of the microtubule proteins α- and γ-tubulin.  
 
The H4-APP cells and PSAPP mouse models we evaluated emulate 
the APP-induced amyloidogenic effects seen in individuals with trisomy 
21. Interestingly, the serum cholesterol and lipid profiles of these 
individuals are abnormal, yet they are protected against atherosclerosis 
(Murdoch, Rodger, Rao, Fletcher, & Dunnigan, 1977; Yla-Herttuala, 
Luoma, Nikkari, & Kivimaki, 1989). It would be interesting to assess 
whether LDLR turnover rates are changed in different tissues of 
individuals with trisomy 21.  
 
Based on our data, we suggest that, rather than a precursor, DS 
and AD dyslipidemia is a consequence of AD-like amyloid pathology 
induced by increased APP. We propose that rescuing the LDLR transport 
to the cell membrane would provide benefit to AD patients. Furthermore, 
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careful evaluation of the mechanisms underlying APP processing as a 
factor in cholesterol metabolism may yield novel therapeutic targets 
against Alzheimer’s.  
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Materials and Methods 
 
Materials: Quantitative-PCR experiments were performed using Applied 
Biosystems, PCR master mixes, human GAPDH endogenous control 
assays, and gene expression assays for human LDLR (assay ID 
Hs01092525_m1). Tissue culture reagents and electrophoresis supplies 
were purchased from Gibco/Invitrogen. Protein concentrations were 
determined with BCATM (Pierce) colorimetric assays. Aβ peptides were 
obtained from American Peptide. 
 
Antibodies: Rabbit anti-LDLR antiserum was a generous gift from Dr. 
Joachim Herz at the University of Texas Southwestern. It was used as 
primary antibody for immunoblots (1:1000) and immunohistochemistry 
assays (1:100) (Ishibashi, et al., 1993). Alternatively, a monoclonal anti-
LDLR antibody from Fitzgerald Industries International (cat.# 10-L55A) 
was used for immunohistochemistry experiments where the co-stain 
targets required rabbit-polyclonal antibodies. Organelle markers for the 
Golgi apparatus, lysosomes, and early endosomes (GM130, LAMP1, and 
EEA1 antibodies, respectively) were purchased from Cell Signaling 
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Technologies, while the KDEL antibody, a marker of endoplasmic 
reticulum was purchased from Stressgen. Monoclonal mouse anti-actin 
(Sigma-Aldrich) and AlexaFluor 488 and 594 (Invitrogen/Molecular 
Probes) antibodies were diluted according to the manufacturer for 
western blot (WB) and immunohistochemistry (IHC) assays, respectively. 
Goat anti-mouse IRDye®800CW and goat anti-rabbit IRDye®680 were 
purchased from LI-COR Biosciences (WB: 1:15,000; IHC: 1:1500). 
Monoclonal anti-α-tubulin and γ-tubulin antibodies were obtained from 
Sigma-Aldrich and diluted according to the company’s specifications. 
Anti-LRP antibody was a generous gift from Dr. Guojun Bu. 
 
Animals: All procedures involving experimentation on animal subjects 
were done in accord with the guidelines set forth by the University of 
South Florida’s Institutional Animal Care and Use Committee (IACUC). 
Mice with the genotype APP+/-, PS1+/- were generated by crossing 
heterozygous PDGF-hAPP(V717F) mice [Swiss-Webster X C57BL/6] with 
PDGF-hPS1(M146L) heterozygotes [Swiss-Webster X C57BL/6] as 
described (Costa, et al., 2007). Non-transgenic (NTG) control mice for 
LDLR-/- mice were C57BL/6J expressing endogenous LDLR (The Jackson 
Laboratory). NTG control mice for APP+/-, PS1+/- were littermates that 
lacked both transgenes. All mice were genotyped by PCR to confirm the 
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presence or absence of PDGF-hAPP (Games, et al., 1995) and PDGF-hPS1 
(Duff, et al., 1996). APP knock-out mice (strain B6.129S7-APPtm1Dbo/J) 
were obtained from The Jackson Laboratory and were genotyped 
according to the provider’s recommendations. Primary neurons were 
obtained from the cortex and hippocampus of E18 NTG mice as described 
(Padmanabhan, et al., 2006). Neurons were grown for one week on poly-
L-lysine-coated 8-chamber slides in neurobasal medium with B27 
supplement. Neurons were then treated for 48 hours with 1 µM 
concentration of either Aβ40 or Aβ42. Cells were then fixed and stained as 
described below in the immunohistochemistry section. 
 
Tissue preparation: Brain tissue was acquired by anesthetizing mice with 
0.1 mg/g Nembutal followed by transcardial perfusion with 0.9% saline 
solution for 8-12 min at 120 mmHg. Whole brains were immediately 
removed for processing. Messenger RNA was extracted by homogenizing 
tissues in TRI reagent (Sigma-Aldrich). Microsomal protein extracts were 
obtained as previously described (Ness, et al., 1986), with minor 
modifications: 0.25M sucrose was prepared with protease inhibitors (1 
tablet mini-Complete/ 10 ml sucrose, Roche Applied Science). Samples 
were dounce homogenized and spun at 10,000 x g for 10 min. Then, 
supernatants were spun once at 30,000 x g for 90 min in a fixed-angle 
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rotor. Microsome pellets were resuspended in PBS with 10% glycerol and 
protease inhibitor cocktail (Roche). Brains for immunohistochemistry 
assays were fixed for 24 hrs in 4% para-formaldehyde. The fixed tissues 
were cryo-protected in successive sucrose gradients as previously 
described (Nilsson, et al., 2001). Brains were frozen on a temperature-
controlled freezing stage, coronally sectioned (25 µm) on a sliding 
microtome, and stored in a solution of PBS containing 0.02% NaN3 at 
4oC.  
 
Quantitative RT-PCR: Five micrograms of DNase-treated mRNA were 
reverse-transcribed with SuperScript® VILOTM cDNA Synthesis Kit 
(Invitrogen) using random hexamers according to the manufacturer’s 
instructions. Quantitative RT-PCR was performed according to the 
manufacturer. Reactions were processed in the 7500 FAST System with 
its Sequence Detection Software (SDS) from Applied Biosystems. 
 
Western blots: Unless otherwise indicated, 50 µg (protein) of brain 
microsomes, were denatured with LDS sample buffer according to the 
Invitrogen protocol. Samples were loaded onto 3-8%, 1.0 or 1.5mm Tris-
Acetate gels, and run at 80V for 180 min. Gels were dry- (iBlot, 
Invitrogen) or wet-transferred onto PVDF membranes for 9 min. Non-
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specific protein binding to the membrane was blocked by incubating with 
5% BSA or 7% non-fat dry milk for 90 min at room temperature. Primary 
antibody for actin was diluted 1:10000, while LDLR antibodies were 
diluted 1:1000 in blocking buffer and incubated overnight at 4°C. 
Secondary antibody incubations with either IR-dyes (1:15000) or HRP-
conjugated were performed sequentially for 60 min at room temperature. 
Membranes were washed three times for 10 min with PBS or TBS and 
0.1% Tween-20 after incubation with each antibody. Membranes were 
scanned and analyzed with the LI-COR Odyssey and accompanying 
software or developed using ECL reagent.  
 
Immunohistochemistry: H4 and H4-APP cells were cultured in 8-chamber 
slides for 3 days prior to immunostaining. Cells were then fixed in ice-
cold methanol or 4% para-formaldehyde for 15 min at room temperature 
and incubated with blocking buffer (described below). Brain sections were 
mounted onto Colorfrost®/Plus slides (Fisher Scientific) Non-specific 
binding was blocked in NGS (10% normal goat serum, 0.2% Triton X-
100, and 0.02% NaN3 in Tris-buffered saline (TBS)) or in NGS without 
detergents for non-permeabilizing experiments, for 120 min at room 
temperature. Primary antibodies were incubated overnight at 4°C in 10% 
NGS. After four, 5 min washes in TBS, slides were incubated with 
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AlexaFluor -594 and -488 (anti-rabbit and anti-mouse, respectively) 
secondary antibodies in 10% NGS for 60 min at room temperature and 
washed in TBS. Slides were stained with Hoechst (1µg/ml in PBS) for 2 
min to reveal cellular nuclei and mounted using GelMount (Fisher 
Scientific). Staining was analyzed with the Zeiss AxioImager.Z1 and 
AxioVision software using 5x/0.16 or 40x/0.75 dry ECPlan-NeoFluor 
objectives where specified. Images were captured at room temperature 
with an AxioCam MR3 camera. Fluorochromes used were DAPI, DsRed, 
and FITC. The magnified hippocampal cell image in figure 4A was 
modified in Adobe Photoshop by changing the brightness and contrast to 
both the NTG and PSAPP cell images equally and simultaneously. 
 
Image quantification: LDLR, LRP, γ and α-tubulins, and APP were 
quantified using ImageJ as described in Figure S2. Analysis of figures 3 
and 4 were performed by the following procedure: images scanning the 
entire wells for H4, H4-APP, and no-primary-antibody negative controls 
were obtained. These images were taken at 100x and using the same 
exposure time for the channel corresponding to LDLR. We discarded 
pictures containing artifacts (such as those with cells damaged by the 
pipette tip), images from the edges of the wells (due to potential artifacts 
caused by the rubber gasket), and fields containing less than 200 nuclei. 
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We obtained the integrated density (I.D.) of each field and the number of 
cell nuclei using ImageJ (Abramoff, 2004; Rasband, 1997-2009). We 
divided the I.D. by the number of cell nuclei to generate the amount of 
plasma membrane LDLR/cell (I.D./cell). The I.D./cell for the negative 
control was subtracted from the I.D./cell of H4 and H4-APP cells. The 
average of the values for each condition was compared.  
 
Statistical analyses: All data reported were obtained from independent 
experiments. Data were plotted as ±SE of the mean. P-values were 
obtained from paired t-test analyses. 
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Figures 
 
Figure 1. LDLR mRNA and protein are upregulated in H4-APP cells 
compared to H4 controls. 
(A) RT-PCR quantification of LDLR mRNA expression level in H4 and H4-
APP cells (n = 3; *p = 0.04). LDLR threshold cycle values were 
normalized to GAPDH. (B) Western blot for LDLR in whole-cell lysates 
from H4 and H4-APP cells. Lane 1 contains liver whole-cell lysate from a 
NTG mouse. (C) Quantification of western blot (n = 3; *p = 0.01). All 
bands for LDLR were quantified and their values shown in this graph. The 
LDLR band densities were normalized to the actin band in each lane. RT-
PCR and western blot experiments were conducted in triplicate. 
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Figure 2. LDLR distribution is altered in H4-APP cells compared to 
H4 controls.  
(A) Immunohistochemistry imaging at 400x magnification of LDLR and 
LRP in H4 and H4-APP cells. Red signal corresponds to LDLR or LRP as 
indicated and blue signal corresponds to Hoechst-labeled cell nuclei. 
Arrowheads point to three examples of a dense perinuclear LDLR-positive 
signal present in H4-APP cells. (B) Larger image of a selected cell from 
panel 2A; the arrowhead points to an LDLR-positive density. (C and D) 
Quantification of the percentage of cells with perinuclear density of 
fluorescent signal in LDLR (C) and LRP (D), which is described in more 
detail in supplemental figure 2. 
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Figure 3. Surface LDLR is reduced in H4-APP cells compared to H4 
controls. 
H4 and H4-APP cells were immunostained for LDLR in the absence of 
detergents to prevent permeabilization of the plasma membrane. (A) 
Images magnified at 400x showing LDLR signal (red) and nuclei (blue) 
for H4 and H4-APP. (B) Zoomed image of one cell isolated from panel A. 
(C) Quantification of the average LDLR-positive signal per cell showing a 
32% reduction of LDLR on the membrane of H4-APP cells (*p = 0.03). 
The average of the ratio of the total LDLR intensity and the number of 
cell nuclei for the H4 condition was equaled to 100%. The H4-APP ratio 
was divided by the H4 ratio of LDLR intensity per cell; A total of ~18,000 
cells were taken into account from three independent experiments. 
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Figure 4. Aβ42 alters LDLR localization in primary neurons of NTG 
mice.  
Primary neurons were obtained from E18 fetuses, plated and grown for 
one week, and treated with 1 µM Aβ40 or Aβ42 for 48 hours. Cell surface 
LDLR was immunostained (red). (A) Image of primary neurons from cells 
treated for 48 hours with 1µM Aβ42 scrambled peptide (as positive 
control), Aβ40, and Aβ42; image is magnified 630x. (B) Zoomed image 
isolating one cell in each field of panel A.  The negative control 
corresponds to staining in the absence of primary antibody. 
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FIGURE 5. LDLR is abundant in the trans-Golgi network of H4-APP 
cells.  
H4 and H4-APP cells were co-stained for LDLR and different organelle 
markers.  A and B show Golgi apparatus at low and high magnification, 
respectively. C and D show LDLR co-stained with lysosomal marker at low 
and high magnification, respectively. E and F show LDLR co-stained for 
endosomes at low and high magnification respectively. G and H show 
LDLR co-stained with endoplasmic reticulum at low and high 
magnification, respectively. A, C, E, and G were taken at 400x, while B, 
D, F, and H are zoomed images.  
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Figure 6. Brain LDLR is increased in PSAPP mice and decreased in 
APP-/- mice compared to controls.  
Whole-cell lysates were prepared from brains of 10-month old PSAPP, 
APP-/-, and age-matched non-transgenic control mice for western blot 
analyses; liver whole cell lysates were prepared from NTG and LDLR-/- as 
positive and negative control homogenates, respectively. (A) Western 
blot for LDLR, APP, and actin from PSAPP and NTG control lysates. (B) 
Quantification of LDLR signal normalized to actin in western blot of panel 
A (n = 5; *p = 0.05). (C) Western blot for LDLR and actin from NTG and 
APP-/- mice. (D) Quantification of LDLR signal normalized to actin in 
western blot of panel C (nNTG = 3 and nAPP-/- = 4; *p = 0.04).  
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Figure 7. LDLR is increased and delocalized in the hippocampus of 
PSAPP mice compared to NTG controls. 
(A) Representative images at 5x magnification of immunohistochemistry 
staining of the CA3 region of the hippocampus and an enlarged view of a 
representative hippocampal cell surrounding the neuronal layer of a 
PSAPP and NTG mouse. Mice were 10-month old PSAPP and NTG. LDLR 
signal is in red and cell nuclei are in blue. Arrowhead in PSAPP 
hippocampal neuron indicates the concentration LDLR-positive signal. (B) 
Quantification of LDLR-positive signal normalized by the DAPI signal in 
hippocampus of PSAPP and NTG mice. Experiments were done in 
triplicate using brain sections of 8 mice for each condition.  
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Figure 8. γ-tubulin signal is more widely distributed in H4-APP 
cells compared to H4 controls. 
(A) Immunohistochemistry imaging at 400x magnification of LDLR and γ-
tubulin in H4 and H4-APP cells. Red, green, and blue signals correspond 
to LDLR, γ-tubulin, and cell nuclei, respectively. Arrowheads indicate 
three examples of H4-APP cells containing greater area of γ-tubulin signal 
distribution. (B) Larger image of a selected cell from the same slide. 
Merged images in A and B show the location of LDLR in relation to γ-
tubulin and the nucleus. (C) Percentage of diffuse γ-tubulin signal in H4 
compared to H4-APP cells. Quantification is described in further detail in 
supplemental figure 2. 
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Figure 9. α-tubulin is less widely distributed in H4-APP cells 
compared to H4 controls.  
(A) Immunohistochemistry imaging at 400x magnification of LDLR and α-
tubulin in H4 and H4-APP cells. Red, green, and blue signals correspond 
to LDLR, α-tubulin, and cell nuclei, respectively. Arrowheads indicate 
three examples of H4-APP cells containing less diffuse α-tubulin. (B) 
Larger images of selected cells from panel A. Merged images in A and B 
show the location of LDLR in relation to α-tubulin and the nucleus. (C) 
Percentage of diffuse α-tubulin signal in H4 compared to H4-APP cells. 
Quantification is described in further detail in supplemental figure 2. 
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Figure 10. Proposed mechanism by which APP/Aβ overexpression 
diminishes LDLR trafficking by disrupting microtubule formation. 
Overexpression of APP/Aβ causes microtubule destabilization by altering 
the centrosome, and consequently, polymerized microtubules. As a 
result, LDLR trafficking from the TGN to the plasma membrane is 
impaired. Therefore, LDLR accumulates in the TGN. The implications are 
that the cell is unable to import cholesterol effectively, which causes 
transcriptional activation of the LDLR gene.  
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Supplemental figure 1. APP overexpression in H4-APP cells 
causes aberrant localization in the cell.  
(A) Immunohistochemistry imaging at 400x magnification of LDLR and 
APP in H4 and H4-APP cells. Red, green, and blue signals correspond to 
LDLR, APP, and cell nuclei, respectively. (B) Quantification graph of 
diffuse APP signal between H4 and H4-APP cells. (C) Western blot of APP 
in H4 vs. H4-APP cells; actin was used as a loading control. (D) 
Quantification of western blot in (C); quantification is described in more 
detail in supplemental figure 2. 
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Supplemental figure 2. Quantification of staining using Image J.  
(A) Representative image of H4 APP cells for analysis. The cells have 
been stained for LDLR. (B) Histogram generated from ImageJ based on 
the image shown in panel A. Pixel gray value is the color of the pixel on a 
scale of 0 to 255, with 0 being absolute black and 255 being absolute 
white. (C) Magnification of the histogram in panel B. In this 
representative histogram, the mean pixel value is 11.801, and the 
standard deviation of the histogram is 23.217. In order to identify the 
intensely stained perinuclear density, the image was thresholded at 3 
standard deviations from the mean. At this threshold, only pixels with a 
gray value of 81 or greater were identified as positive stain (dark gray 
region in right tail). Identification of total cellular staining was done with 
the image thresholded at 0.5 standard deviations from the mean of the 
image, so all pixels with a value of 21 or greater were identified as 
positive stain (light gray region and dark gray region). For tubulin 
staining, staining outside of the density was defined as that falling 
between 0.5 standard deviations and 3 standard deviations (light gray 
region only). D) Image showing thresholding of the image shown in panel 
A at 3 standard deviations. Note that only intense staining is identified at 
this threshold. E) Further identification of the intense perinuclear density 
based on the criterion that the region be at least 1000 square pixels in 
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area. F K) Representative image of H4 cells stained for LDLR, 
thresholded, and perinuclear densities identified as described in A E. 
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DISCUSSION 
 
 The novel contributions of the work presented in this dissertation 
encompass the study of LDLR in the pathogenesis and progression of AD 
from two different perspectives: (1) evaluation of the adequacy of the 
LDLR-/- model for the study of AD, and (2) investigation of the effects of 
APP/Aβ overexpression on LDLR. Initially, the literature on LDLR and AD 
shows significant contradictions. We do not argue that these data are 
erred, rather that their differences are the consequence of the methods 
employed. In population studies, we suspect that the genetic makeup 
inherent to the different populations studied by the authors of these 
reports contains SNPs that can attribute unique differences in the LDLR 
structure and function. Moreover, different environmental pressures may 
also play a role in unmasking risk of disease processes by LDLR. These 
differences may not be significant to the normal LDLR function in 
regulating serum cholesterol. Yet, they may affect LDLR-mediated 
processes in the CNS. Seemingly miniscule changes to LDLR function 
could suffice to contribute to disease. The end result could be that each 
region and population may have unique etiological processes of AD 
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pathogenesis. This suspicion becomes more valid when considering that 
AD is likely to be the product of multiple contributing sources, as it is to 
be expected of diseases of aging where genetic etiologies are only one 
contributing factor.  
 
 Previous efforts undertaking the study of LDLR and AD, specifically 
projects that used the LDLR-/- mouse to characterize its effect in the 
CNS, are very valuable. However, our results suggest that the LDLR-/- 
mouse may be inadequate for studying the effects of the absence of LDLR 
in the CNS. Therefore, and particularly in the area of AD, the PDAPP x 
LDLR-/- and Tg2576 x LDLR-/- mouse models are not suitable for 
determining whether the lack of LDLR may prevent, stave off, or worsen 
the disease process (Cao, et al., 2006; Fryer, et al., 2005). Instead, the 
data reported by these groups reveal important information about the 
mice themselves irrespective of LDLR-mediated binding of apoE.  
 
The two major conclusions of these separate studies are that lack 
of LDLR had no effect in the AD process and that the lack of LDLR 
increased AD pathology and cognitive decline. In 2006, soon after these 
conflicting results were published, Tveten et. al. reported having 
identified two novel splice-variants of LDLR (Tveten, et al., 2006). One of 
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them, the LDLRΔ4, was of interest to us because the knockout scheme for 
the LDLR-/- mouse used exon 4 as part of the knockout strategy. 
Specifically, Ishibashi et. al. inserted a neomycin cassette within exon 4; 
the cassette codes for a poly-adenylation site at the 3’ end of its 
sequence (Ishibashi, et al., 1993). As a result, transcription of the LDLR 
is incomplete, and generates a truncated LDLR that lacks its intra-
membranous sequence and therefore it cannot be incorporated into a 
vesicle for transport to the plasma membrane.  
 
We hypothesized that exon 4 skipping during transcription would 
bypass the poly-A site and continue transcribing exons 5-18. Indeed, 
after RT-PCR analyses, we discovered that the LDLR-/- mouse was 
capable of producing LDLR mRNA lacking the exon 4 sequence. We 
confirmed these results by sequencing the cDNA obtained from the mice. 
Quantification of LDLRΔ4 mRNA levels revealed transcriptional 
upregulation of the splice-variant suggestive of a compensatory 
mechanism. This finding is provocative as it discovers a phenomenon that 
poses an obstacle for the generation of transgenic, knockout mice.  
 
The next step was to determine if the splice variant generated a 
functional protein. Consequently, we tested a total of 14 antibodies as a 
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means of identifying LDLRΔ4 protein. In western blotting experiments, 
most antibodies detected many non-specific bands, which made it difficult 
to confirm that a band located at the predicted molecular weight for 
LDLRΔ4 could in fact be this protein. Other antibodies were effective at 
detecting LDLR in liver, but fell short in brain homogenates, where 
western blots showed no bands. We suspect that the problem arises 
because the region coded by exon 4 is not immunogenic and LDLR 
expression is very low in the CNS. In 1987, Brown and Goldstein 
encountered similar problems in rabbits: “Several attempts to 
demonstrate the presence of LDL receptors in rabbit brain and spinal cord 
were unsuccessful because of the lack of high affinity antibody that 
recognizes the rabbit LDL receptor and the large amounts of myelin that 
limited recovery of the membrane proteins” (Hofmann, Russell, 
Goldstein, & Brown, 1987). They turned to the bovine brain as a means 
to recover a larger fraction of membrane proteins and successfully 
detected LDLR. The difficulty of detecting LDLR in brain led us to try a 
proteomic approach. We tried to separate LDLR and LDLRΔ4 by running 
brain and liver homogenates of both NTG and LDLR-/- mice on a gel and 
staining with Coomassie blue. We used mass spectroscopy and 
sequenced a total of 12 bands and were unable to detect either form of 
LDLR. We then enriched the amount of these LDLR/LDLRΔ4 by performing 
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an immuno-precipitation. Again, the data coincided with neither LDLR nor 
LDLRΔ4 sequences. Finally, since the isoelectric points of the full-length 
LDLR and the predicted exon 4-lacking variant differ sufficiently (~4.7 to 
~7.8) we separated them using 2D-gels.  
 
We were fortunate to have received a polyclonal rabbit antibody 
from Dr. Joachim Herz (Russell, et al., 1984). This antibody gave clear 
bands from brain and liver samples of NTG mice in western blots at the 
expected molecular weight of LDLR. Furthermore, in LDLR-/- brain 
microsomal protein preparations, the Herz antibody revealed bands at a 
slightly lower molecular weight for LDLR (shown in Chapter 2). We 
interpreted this result as the detection of LDLRΔ4. It is critical to note 
that the lack of a specific antibody for LDLRΔ4 limited the confirmation of 
the ability of the cell to make this protein. However, despite this caveat, 
we felt confident that the most likely explanation of the detection of this 
band was that it was the result of the upregulated transcription of the 
LDLRΔ4 mRNA. As a result, we performed the IHC experiments to 
characterize the location and function of LDLRΔ4 in LDLR-/- mice 
compared to the full-length LDLR in NTG mice, as noted in chapter 2. We 
communicated these results to Dr. Herz, who was of the opinion that the 
LDLR bands in LDLR-/- lanes are the result of non-specific binding of the 
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LDLR-/- antibody. Rather than creating an impasse, these opinions show 
the necessity of developing an antibody raised against an immunogenic 
region specific for LDLRΔ4. We attempted to induce these antibodies in 
BALB/c mice and rabbits, but the unique signature of the LDLRΔ4 is 
insufficient to generate an immune response, and therefore, our efforts 
were not fruitful.  
 
The abovementioned obstacles did not mar our investigations, as 
our subsequent data suggested that LDLRΔ4 might play a role in AD 
pathogenesis. We found that the transcription level of this LDLR isoform 
is increased two-fold in amyloid-ridden PSAPP mice. Because of the ability 
of this LDLR species to co-localize with apoE, further work should focus 
on identifying the kinetics dictating the interaction between LDLRΔ4 and 
apoE. The predicted tertiary structure of the putative apoE-binding region 
on LDLRΔ4 strikingly resembled that on the full-length counterpart. Also, 
it is possible that LDLRΔ4 may have other ligands, the identification of 
which will reveal important information about cholesterol metabolism in 
the CNS. Proteomic-based screens could help answer these questions. 
However, it will be difficult to make significant progress in this aim until 
we can generate antibodies specific to LDLRΔ4.  
 
 207 
 
There is no direct evidence indicating that serum cholesterol 
crosses into the CNS (Dietschy & Turley, 2004). The logical suspicion that 
this might be the case is well founded: first, the suckling period, when 
dietary cholesterol is introduced to the organism for the first time, 
coincides with the highest cholesterol requirement for CNS growth and 
myelination (Dietschy & Turley, 2004); second, endothelial cells that 
make up the blood-brain barrier express nuclear receptors that regulate 
the expression of cholesterol transporters like ABCA1 (ATP-binding 
cassette A1) (Ohtsuki, et al., 2004; Panzenboeck, et al., 2002); finally, 
mRNA for LDLR is found in the brain (Hofmann, et al., 1987). Together, 
these observations support the notion that serum lipoproteins could enter 
the CNS. On the contrary, experimental data indicate that the CNS is 
largely independent from peripheral cholesterol metabolism. The 
availability of a mouse model that favors lipid removal from periphery 
selectively from the CNS would be very powerful for characterizing such 
differences. Furthermore, the onset of many neurodegenerative diseases 
such as vascular dementia, Niemann-Pick’s disorder, and AD are 
associated with cholesterol dysregulation. Thus, the LDLR-/- mouse 
becomes a powerful tool to study the differences between peripheral and 
CNS cholesterol metabolism, for instance, by crossing this mouse with 
other models of neurodegenerative diseases and documenting changes in 
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the disease outcome. Inherently, LDLRΔ4 may be a key participant of 
these processes and would be characterized in subsequent research 
efforts. 
 
An important implication of these results is that alternative splicing 
must be taken into account when designing knock-out and siRNA 
mechanisms. To our knowledge, the only other example of a related 
knockout escape by alternative splicing was described for the sorLA/LR11 
knock-out mouse during the preparation of this work. The sorLA/LR11 
knock-out mouse also undergoes an identical splice-mediated elusion of 
the knock-out scheme as we preliminarily reported in the LDLR-/- mice 
(Abisambra, et al., 2007; Dodson, et al., 2008). The results also 
implicate deletion of exon 4, the site where the new RNA cleavage and 
poly-adenylation site was introduced in the sorLA/LR11-/- mouse. At the 
mRNA and protein level, the authors found similar results to ours, 
implying that this alternative splicing activity may be common in the 
LDLR family of proteins. Together, these results support the conclusion 
that exon skipping must be considered while targeting an exon for knock-
out mouse generation. More research to determine the normal function of 
splice variants of LDLR and SorLA/LR11 should prove valuable in 
determining if these shortened proteins work independently or in concert 
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with the cholesterol and apoE metabolism. Furthermore, search for other 
splicing motifs within gene families may shed light on unprecedented 
regulation of the functions of the products of such gene families. In the 
case of LDLR, the exon 4 splice variant may be expressed to eliminate 
ligand competition between apoB and apoE. If so, this phenomenon 
might be a more efficient pathway for apoE metabolism. Participation of 
other LDLR-family members and their splice variants in cholesterol 
regulation remains to be determined. 
 
The second focus of my work is presented in chapter 3. Many 
studies approached the elucidation of links between LDLR and AD by 
modifying the former and documenting changes in the latter. To the 
contrary, our strategy was to determine if the impact of APP/Aβ 
overexpression would modify LDLR. This perspective would not only 
clarify details of apoE metabolism by LDLR, but also do so during APP/Aβ-
promoted disease.  
 
We identified detrimental effects to microtubule organization by 
APP/Aβ overexpression. Due to the critical functions of microtubules 
necessary for cell survival, we suspect that the impact of microtubule 
damage could participate in pathogenesis of AD. For example, changes in 
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cell morphology during disease could be explained by APP/Aβ-induced 
damage to microtubules. Therefore, cytoarchitectural support would be 
compromised leading to the neuritic atrophy. 
 
Another example of microtubule dysfunction is that protein and 
vesicle trafficking could be reduced or inhibited. The implications of 
microtubule damage in this scenario would depend on the particular 
protein or vesicle being affected at any point in time. In our studies, we 
found accumulation of LDLR in the TGN. Furthermore, its localization in 
the plasma membrane was significantly reduced, which indirectly may 
have led to an attempted compensatory increase in its expression.  
 
Microtubule-mediated dysfunction of the LDLR pathway could have 
severe implications for apoE metabolism, and thusly cholesterol 
homeostasis. Presumably, depletion of LDLR from the plasma membrane 
may lead to decreased import of apoE and its lipid contents (including 
cholesterol). This would result in two opposing outcomes that can be 
viewed as an acute and chronic cellular adaptation. 
 
 Reduced cholesterol import inherently leads to low intracellular 
cholesterol levels. Consequently, SREBPs are cleaved from the Golgi 
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apparatus and translocate into the nucleus for transcriptional activation of 
the cell machinery involved in both de novo cholesterol biosynthesis and 
increased production of cholesterol receptors. We find evidence for this 
effect with the detection of increased mRNA and LDLR protein levels. 
Other reports have suggested that certain regions of AD brains have 
increased levels of HMG CoA reductase, the rate-limiting enzyme in the 
cholesterol biosynthetic pathway. Together, these data suggest that the 
cell has induced transcriptional activation of proteins responsible for 
increasing cholesterol production and import. However, other apoE 
receptors like LRP-1, apoER2, and VLDLR follow the same transport as 
LDLR during low intracellular cholesterol conditions. Therefore, APP/Aβ 
destabilization of microtubule dynamics appears to reduce or impedes 
apoE receptor transport to the plasma membrane. As a result, the only 
cholesterol available for the cell is that which is made de novo within 
itself. This single source would increase the time during which the cell 
reaches normal cholesterol levels. It would be interesting to see if slower 
adaptation to decreases in intracellular cholesterol can cause cellular 
stress, lipid peroxidation due to excess lipid concentration on 
membranes, or other byproducts that result in cell toxicity. This would be 
especially impactful for neurons, whose cholesterol requirement is very 
high.  
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Also, cholesterol migration to and storage in membranes would 
inherently increase its rigidity and the formation of lipid rafts. APP 
anchoring within lipid rafts favors the β- and γ- secretase-induced 
amyloidogenic pathway, whereas non-raft APP is mainly cleaved by α-
secretase. Animals fed high cholesterol diets show an increase in amyloid 
plaque formation in rabbits and in transgenic mouse models of AD 
(Howland, et al., 1998; Shie, et al., 2002; Sparks, et al., 1994); 
moreover, in these mice, the high cholesterol diet induced cognitive 
decline (Thirumangalakudi, et al., 2008). In vitro studies showed that 
APP processing is highly dependent upon availability of cellular 
cholesterol. Cholesterol-depleted rat hippocampal primary neurons show 
reduced APP processing into Aβ (Fassbender, et al., 2001; M. Simons, et 
al., 1998) yet favor the generation of non-amyloidogenic APP processing 
by α-secretase (Bodovitz & Klein, 1996; Kojro, et al., 2001).  
 
Therefore, increased Aβ-production could ensue, further feeding 
into deregulation of cholesterol import and production. Chronically, it 
would be difficult to predict if the cell, particularly AD neurons, would 
have too high or too low cholesterol levels. Nonetheless, it would be safe 
to say that cholesterol homeostasis is altered. This may be especially 
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detrimental for cells that require high cholesterol levels like neurons. 
Furthermore, it may well constitute one of the initial steps of 
neurodegeneration in AD.  
 
Other implications for APP/Aβ-mediated microtubule damage may 
be the release of tau. As a microtubule stabilizer, tau levels may increase 
due to the reduction or disorganization of microtubules. Consequently, 
free tau would be available for hyper-phosphorylation and aggregation 
into tangles. It is not clear yet whether free tau becomes more hyper-
phosphorylated than microtubule-bound tau, but the availability of 
phosphorylation sites on it are increased while not bound. 
 
Besides abnormal processing, Aβ levels can also be augmented by 
increasing production of APP. Since the APP gene resides on chromosome 
21, individuals with trisomy 21 (resulting in Down’s Syndrome – DS) are 
subject to higher levels of APP, and thusly Aβ. By the fourth decade, 
these individuals develop signs of dementia, and their brains are heavily 
plaque-ridden. Interestingly, the serum cholesterol and lipid profiles of 
these individuals are abnormal, yet they are protected against 
atherosclerosis. It would be interesting to assess whether LDLR turnover 
rates are changed in different tissues of individuals with trisomy 21. 
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Careful follow-up of these patients may reveal knowledge about the in 
vivo relationship of LDLR and APP overexpression. These potential studies 
could provide insights into the effects and mechanisms by which APP 
overexpression modulates of apoE metabolism. 
 
 We show increased LDLR in APP transgenic mice and APP over-
expressing cells and a decreased LDLR in APP-/- mice. One mechanism 
for this appears to be decreased expression of the protein responsible for 
LDLR turnover, PCSK9. These observations suggest that, rather than a 
precursor, DS and AD dyslipidemia is a consequence of AD-like amyloid 
pathology induced by increased APP. The molecular mechanisms 
underlying these events remain unclear. The scope of our methods does 
not encompass enough data to confirm that these conditions are 
generalized to other models of APP over-expression. Further analysis of 
tissues and serum lipid profiles from AD patients may reveal important 
insights into cholesterol-induced pathogenesis. Regardless, careful 
evaluation of the mechanisms underlying APP processing as a factor of 
cholesterol levels may yield novel therapeutic targets. In this regard, 
PCSK9 inhibitors and activators as a means to manipulate LDLR may 
provide modulation of APP processing into Aβ. 
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In conclusion, we provide further insight into the complicated 
system of cholesterol metabolism in the brain from the perspective of the 
LDLR. Furthermore, we do so on the basis of Alzheimer’s, a condition 
where altered cholesterol levels have an unknown impact on the disease 
pathogenesis and/or progression. Nonetheless, and unexpectedly, our 
work culminates in further detailing a link between APP/Aβ and abnormal 
microtubule formation.  
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APPENDIX A  
 
Activation of the Hepatic LDL Receptor by Thyroid Hormone  
 
 
This appendix was prepared by Dayami Lopez, Jose F. Abisambra 
Socarrás, Mohini Bedi, and Gene C. Ness. 
 
 
Abstract 
 
The question of whether mature sterol regulatory element binding 
protein-2 (SREBP-2) is involved in the transcriptional activation of the 
hepatic low density lipoprotein (LDL) receptor by thyroid hormone was 
investigated.  Western blotting analysis and electrophoretic mobility shift 
assays demonstrated that mature (nuclear) SREBP-2 protein could be 
detected in the nuclear extracts prepared from normal animals but not in 
extracts prepared from either hypophysectomized (Hx) or 
thyroparathyroidectomized (Tx) rats – two hypothyroid states.   
Treatment of Hx rats with T3 restored LDL receptor mRNA levels in about 
1 hr and caused a 6-fold increase 2.5 hrs after T3 administration.  No 
detectable mature SREBP-2 was seen in this time period despite a 
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substantial reduction in serum cholesterol levels caused by T3 treatment. 
The data indicate that SREBP-2 is not required for transcriptional 
activation of the LDL receptor by thyroid hormone suggesting a direct 
effect of this hormone on LDL receptor transcription. 
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Introduction 
 
Hypothyroidism, in both humans and experimental animals, is well 
known to be accompanied by elevated levels of serum cholesterol, 
especially low density lipoprotein (LDL)-cholesterol [1-6].  The effect can 
be reversed by thyroid hormone treatment [5-13].  This property of 
thyroid hormones has been extensively explored in the development of 
thyromimetics as possible anti-cholesterolemic drugs [8,14-16].  Several 
studies have established that the effects of thyroid hormone on serum 
cholesterol levels are due, at least in part, to alterations in expression of 
the hepatic LDL receptor [4, 13, 15, 17-21].  In hypophysectomized rats, 
for example, administration of thyroid hormone rapidly and significantly 
increases hepatic LDL receptor mRNA and protein levels within 1 hour 
[18].  This enhancement in hepatic LDL receptor expression results from 
4- to 5-fold increases in the rate of transcription that occurs 30 to 60 
minutes after giving thyroid hormone [22].  Based on this, it is logical to 
assume that thyroid hormone influences the expression of this gene 
through a direct mechanism involving activation of its nuclear receptors 
(TRs).   
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Independent of any direct effect that thyroid hormone may have via a 
TR, the possibility that induction of hepatic LDL receptors occurs as a 
consequence of reduction in cellular levels of cholesterol, a key factor in 
regulation of the LDL receptor [23-29], cannot be ignored.  In the human 
LDL receptor gene, transcriptional regulation by cholesterol requires a 10-
base pair (bp) element, designated sterol response element-1 (SRE-1) 
[30].  SRE-1 is located in the center of two Sp1 binding sites [30].  In 
vivo, all three elements, the SRE-1 and the two Sp1 sites, are necessary 
for high levels of transcription in the absence of sterols [30].  Putative 
SRE containing regions have been identified in the promoters of the rat 
[31], hamster [31], and mouse [32] LDL receptor genes.           
 
Transcriptional activation through an SRE is mediated by a group of 
proteins known as sterol regulatory element binding proteins (SREBP-1a, 
-1c and -2) [33-40].  SREBPs are synthesized as 125 kDa precursors that 
are attached to the endoplasmic reticulum (ER) membrane and the 
nuclear envelope [41, 42].  Maturation of these transcription factors 
occurs through a proteolytic process that releases their NH2-terminal 
(active) regions, which enter the nucleus, bind to a SRE, and activate 
transcription of a target gene [39, 41].  Sterol regulation of the 
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proteolytic cleavage resides in the formation of a complex between the 
SREBP precursor and another membrane bound protein called the SREBP 
cleavage activating protein (SCAP) [43].  Under high cholesterol levels, 
the SREBP/SCAP complex is retained in the ER preventing SREBP 
processing [43].  Once the ER membrane becomes depleted of 
cholesterol, the SREBP/SCAP complex moves to the Golgi complex where 
proteolytic cleavage of SREBP occurs [43].  Although in cultured cells, the 
three SREBPs appear to act independently and in an apparent redundant 
manner [44], in vivo studies clearly indicate that SREBP-1c is involved in 
the activation of fatty acid and glucose/insulin metabolism related genes, 
whereas SREBP-2 is more specific for genes involved in cholesterol 
metabolism such as the LDL receptor [43].  Thus, SREBP-2 could be 
considered a potential candidate to mediate thyroid hormone’s effects on 
the LDL receptor gene.  Interestingly, increases in mature SREBP-2 
protein levels as a result of thyroid hormone treatment have been 
recently reported by Shin and Osborne [45].  In that study, changes in 
mature SREBP-2 protein levels seen in the presence of thyroid hormone 
directly correlated with changes in LDL receptor mRNA levels [45]. 
 
In view of these findings, we set out to determine whether an increase 
in mature SREBP-2 might precede or occur simultaneously and thus 
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might mediate the increase in hepatic LDL receptor expression caused by 
thyroid hormone. No detectable mature SREBP-2 was found in the first 
2.5 hrs following thyroid hormone administration when hepatic LDL 
receptor mRNA was maximally induced.  These data indicate that the 
rapid transcriptional activation of the rat hepatic LDL receptor by thyroid 
hormone is not dependent on mature (nuclear) SREBP-2 protein. This 
finding supports a mechanism involving a direct effect of thyroid hormone 
on the rat hepatic LDL receptor gene. 
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Materials and Methods 
 
Animals. Normal, hypophysectomized (Hx), and 
thyroparathyroidectomized (Tx) male Sprague-Dawley rats weighing 125 
to 150 g were purchased from Harlan Industries (Madison, WI).  All 
protocols involving animals were approved by the University of South 
Florida IACUC Committee.  Normal and Hx rats received regular water and 
Purina Rodent Laboratory Chow 5001 ad libitum.  The Tx animals were 
maintained on 2% (w/v) calcium gluconate as their drinking water and an 
iodine-deficient diet (Harlan Industries).  All animals were housed in a 
light-controlled reversed cycle room with 12 hrs of light followed by 12 
hrs of darkness.  Hx and Tx rats were used in experiments 10 to 21 days 
following surgery.  The status of the Hx rats was confirmed by failure to 
gain weight, whereas the status of the Tx rats was confirmed by weight 
gains of one-half the rate of normal rats.  Some rats received an injection 
of triiodothyronine (T3; Sigma Co., St. Louis, MO) subcutaneously at a 
dose of 10 µg per 100 g of body weight, 1 to 2.5 hours before 
euthanatization.  Rats were euthanatized at the fourth hour of the dark 
period by an isofluorane overdose.  Liver portions were quickly removed 
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for preparation of nuclear extracts and RNA.  Serum samples were 
prepared from all the rats.  Free-T3 levels in the serum of these animals 
were determined using an ELISA kit from Research Diagnostics, Inc. 
(Flanders, NJ).  Serum cholesterol levels were determined using Infinity 
Reagent from Sigma Co., (St. Louis, Mo).   
 
Materials.  The BCA protein assay kit, pre-cast 4-20% sodium dodecyl 
sulfate-polyacrylamide gels (SDS-PAGE), and the SuperSignal ULTRA 
Chemiluminescent Substrate were purchased from Pierce (Rockford, IL).  
Pre-stained protein molecular weight markers and SYBR Green Real-time 
PCR supermix were obtained from BioRad Labs (Hercules, CA).  
Nitrocellulose membrane and BioMax-MR films were purchased from 
Fisher Scientific (Norcross, GA).  Antibody specific for SREBP-2 and the 
horseradish peroxidase-conjugated goat-anti-rabbit secondary antibody 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  The 
free-T3 ELISA kit was from Research Diagnostics, Inc. (Flanders, NJ).  
TRβ1 specific antisera was purchased from Upstate Biotechnology Inc. 
(Lake Placid, NY).  Oligonucleotides were synthesized by Integrated DNA 
Technologies (Coralville, IA).  Klenow enzyme, restriction enzymes, and 
the Reverse Transcriptase System were purchased from Promega Corp 
(Madison, WI).  [α32P]dCTP (3000 Ci/mmol) was obtained from Perkin 
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Elmer/New England Nuclear (Wilmington, DE).  TRI Reagent was obtained 
from Molecular Research Center (Cincinnati, OH).  The Turbo DNA-free 
Kit was purchased from Ambion.  All other chemicals were obtained from 
Fisher Scientific or Sigma Chemical Co. (St. Louis, MO).     
 
Preparation of nuclear extracts.  Rat liver samples, 400 mg, were 
minced and homogenized in 10 ml of buffer A (15 mM Tris-HCl, pH 7.5; 
15 mM KCl, 15 mM β-mercaptoethanol, 2 mM EDTA, 0.5 mM EGTA, 0.15 
mM spermine, 0.5 mM spermidine, 1.9 M sucrose, 0.1% Triton X-100 and 
0.1 mM PMSF) using a motor-driven serrated Teflon pestle in a 20 ml 
glass Potter-Elvehjem homogenizer.  The homogenate was filtered 
through nylon gauze and layered over an equal volume of the same 
buffer lacking Triton X-100.  Samples were centrifuged at 90,000 x g for 
90 minutes at 4°C.  The white nuclei pellet was resuspended in 1 ml of 
buffer B (15 mM Tris-HCl, pH 7.5; 15 mM NaCl, 60 mM KCl, 15 mM β-
mercaptoethanol, 0.15 mM spermine, 0.5 mM spermidine, 0.34 M sucrose 
and 0.1 mM PMSF) and centrifuged at 3,000 x g for 5 minutes at 4°C.  
The resulting pellet was resuspended in 1 ml of Buffer C (420 mM NaCl, 
20 mM HEPES, pH 7.9, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 1 mM 
Na3VO4, 1 mM Na4P2O7, 1 mM DTT and 0.5 mM PMSF) and incubated at 
4°C for 30 minutes on a rotating wheel to extract nuclear protein.  The 
 277 
 
mixture was then centrifuged for 15 minutes at 8,400 x g.  Supernatants 
corresponding to the nuclear extracts were aliquoted and stored at -70°C 
until used.  Protein concentrations were determined using the BCA 
protein assay kit (Pierce). 
 
 Western blotting analysis.  Ten µg of liver nuclear protein were 
denatured at 100oC in loading buffer and subjected to electrophoresis on 
a pre-cast 4-20% SDS-PAGE.  Pre-stained molecular weight markers 
(Bio-Rad Labs) were applied to one lane.  After electrophoresis, samples 
were electroblotted onto nitrocellulose membranes (0.2 µm pore) in 
buffer containing 0.25 M Tris hydrochloride (Tris-HCl; pH 8.3), 1.92 M 
glycine, and 20% (v/v) methanol for 16 hours at 4oC.  To verify equal 
protein loading, membranes were stained with 0.1% (v/v) Ponceau 
Solution in 5% (v/v) acetic acid (Sigma Co.) and destained in water.  
Blocking was performed in 5% (w/v) non-fat dry milk in TTBS (10 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 0.01% Tween-20) for 30 min at room 
temperature.  Western blotting analysis for SREBP-2 and TRβ1 (control) 
proteins was carried out with a 1:1000 of rabbit polyclonal antibodies to 
SREBP-2 and TRβ1, respectively, in TTBS supplemented with 2% (w/v) 
non-fat dry milk and incubated overnight at 4oC.  Immunoreactive 
proteins were then visualized using a 1:10,000 dilution of horseradish 
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peroxidase-conjugated goat anti-rabbit antisera (Santa Cruz 
Biotechnology) in TTBS supplemented with 2% (w/v) non-fat dry milk 
and the SuperSignal ULTRA Chemiluminescent Substrate method 
(Pierce).  Washes after each antibody (six total) were performed with 
TTBS supplemented with 0.5% (w/v) non-fat dry milk.  Multiple 
exposures ranging from 5 seconds to 20 minutes were made.   
 
Electrophoretic mobility shift assays.  Electrophoretic mobility shift 
assays were performed as previously described [46] except that binding 
reactions were carried out at room temperature for 30 minutes.  
Complementary oligonucleotides containing the rat LDL receptor SRE 
motif located at bp -242 to -234 were synthesized and labeled using 
[α32P] dCTP and the Klenow polymerase fill-in reaction with 
oligonucleotide pairs constructed to provide overhangs.  The sequence of 
one strand of the complementary oligonucleotide probe was 5’-
TTTTTGAAAATCACCCCACTGCAGACTCCT-3’.  Binding reactions were 
carried out in 20 µl volumes with the indicated proteins and 25 fmol of 
labeled probe.  SREBP-2 specific antibody was added as indicated.  The 
samples were run on 6% acrylamide/bisacrylamide gels.  Gels were then 
vacuum-dried and exposed to X-ray films at -80oC for 12-24 hours. 
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Real-time Reverse-transcriptase PCR.  Total hepatic RNA was isolated 
using the guanidinium thiocyanate-phenol-chloroform extraction method 
employing TRI Reagent (Molecular Research Center).  This method 
consistently yields 5-8 µg of RNA per mg of tissue.  Fifty µg of total RNA 
was first DNase I treated using the Turbo DNA-free kit (Ambion).  After 
inactivation of the DNase I enzyme, 1 µg of the DNA-free RNA was 
reverse transcribed using Promega’s Reverse transcriptase system and 
random primers as per the manufacturer’s instructions.  Real-time PCR 
reactions were performed using 100 ng of ssDNA, the BioRad SYBR Green 
real-time RT-PCR kit, and the iCycler real-time PCR system.  Rat LDL 
receptor specific primers used were 5’-GGGCTGGCGGTAGACTGGATC-3’ 
(sense) and 5’-CAATCTGTCCAGTACATGAAGC-3’ (antisense).  The size of 
the LDL receptor fragment that is amplified using these primers is 200 
bp.  Primers specific for 18S (5’-GTAACCCGTTGAACCCCATT-3’ and 5’-
CCATCCAATCGGTAGTAGCG-3’) were used as the internal control for 
these studies.  The parameters for the PCR reactions were denaturation 
at 95°C for 3 minutes, followed by 39 cycles of denaturation at 95°C for 
30 seconds, annealing at 63°C for 30 seconds, and extension at 72°C for 
30 seconds.  The melt curve was performed starting at 55oC with 
increases of 0.5oC every 30 seconds for 80 repeats ending at 95oC.  
Quantitation of the results was performed using the Comparative CT 
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method. 
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Results and Discussion 
 
To examine whether levels of mature (nuclear) SREBP-2 protein in 
liver correlate with serum levels of thyroid hormone, liver nuclear 
extracts and serum samples were prepared from normal, 
hypophysectomized (Hx) and thyroparathyroidectomized (Tx) rats.  
Western blotting analysis for mature SREBP-2 protein and measurements 
of free-T3 levels in the serum were performed as described in Material 
and methods.   As shown in Fig. 1, SREBP-2 protein was detected in 
nuclear extracts prepared from normal animals but not in nuclear 
extracts prepared from either Hx or Tx rats.  Free-T3 levels for the normal 
and Hx rats were 4.35 and 1.75 pg/dl, respectively, whereas Tx rats’ 
free-T3 levels were too low to be determined (Fig. 1).  Changes in SREBP-
2 levels appear to be specific for this protein, since control Western blots 
obtained using a thyroid hormone receptor β1 (TRβ1) specific antibody 
demonstrated that TRβ1 levels were unaffected under the same 
conditions (Fig. 1).     
 
To further assess the presence of mature SREBP-2 protein in the 
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normal, Hx and Tx nuclear extracts, electrophoretic mobility shift assays 
were carried out using the rat LDL receptor SRE motif located at bp -242 
within the promoter region of this gene (GenBank accession number 
AY675581).  As shown in Fig. 2A, formation of a DNA/protein complex 
between liver nuclear extracts and the SRE probe was observed in the 
presence of extracts from normal (N; lanes 2-4) but not from Tx (lanes 
5-8) or Hx (lanes 9-11) rats.  Although these results are in complete 
agreement with the Western blot data presented in Fig. 1, it was still 
necessary to determine whether SREBP-2 was part of the DNA-protein 
complex observed using the normal samples.  To examine this, 
electrophoretic mobility shift assays were performed in the presence of a 
SREBP-2 specific antibody.  As shown in Fig. 2B (lane 4), the addition of 
SREBP-2 antibody (5 µg IgG) to the binding reactions was able to reduce 
DNA-protein complex formation between normal liver nuclear extracts 
and the rat LDL receptor SRE motif.  Once again, no binding between Tx 
nuclear extracts and the SRE motif was observed (Fig. 2B, lanes 3 and 
5). 
 
Participation of SREBP-2 in the thyroid hormone-dependent regulation 
of the LDL receptor gene was originally suggested by Shin and Osborne 
[45].  In that report, it was demonstrated that the SREBP-2 gene is 
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regulated by thyroid hormone mainly at the transcriptional level via 
binding and activation of a putative DR-4 TRE site located in the SREBP-2 
promoter [45].  This resulted in increases in mature SREBP-2 protein 
levels with comparable increases in LDL receptor mRNA [45].  However, 
considering the rapid time course (30 to 60 minutes) for the T3-mediated 
activation of LDL receptor transcription [22], it is logical to assume that if 
SREBP-2 is responsible for the changes seen in hepatic LDL receptor 
expression under these conditions, an increase in mature SREBP-2 
protein levels should precede or occur simultaneously with the 
enhancement in LDL receptor transcription.  To examine this possibility, 
Hx rats were injected subcutaneously with 10 µg of T3 per 100 g of body 
weight, 1 to 2.5 hours before euthanatization.  Hepatic nuclear extract 
preparation and Western blotting analysis for mature SREBP-2 protein 
were performed as described in Fig. 1.  Surprisingly, no mature SREBP-2 
protein was detected in any of the nuclear extracts prepared from the Hx 
animals even at 2.5 hours after T3 injection (Fig. 3).  Hepatic LDL 
receptor mRNA levels were returned to near normal 1 hr after T3 
administration.  At 2.5 hrs after T3 treatment hepatic LDL receptor mRNA 
levels were increased 6-fold over those of the Hx animals (Fig. 3).  
Serum cholesterol levels were substantially decreased by T3 treatment to 
levels below those of the normal (Fig. 3).  This data clearly indicates that 
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SREBP-2 is not required for transcriptional activation of the hepatic LDL 
receptor after thyroid hormone treatment.  In the studies by Shin and 
Osborne [45] hypothyroid mice were treated daily for 4 days with 100 µg 
of T3 per 100 g of body weight.  This dose of T3 is much higher than that 
used in the present study.  In the previously reported study [45] any 
rapid effect of thyroid hormone on hepatic LDL receptor mRNA would 
have been overlooked.  It is well established that T3 acts to quickly 
increase transcription of the hepatic LDL receptor gene [4, 18, 22].   
The data presented in this report demonstrate that mature SREBP-2 is 
not required for transcriptional activation of the rat LDL receptor by 
thyroid hormone.  These findings support a mechanism involving a 
primary effect of thyroid hormone on the LDL receptor gene via activation 
of the TRs.  In fact, we have identified two promoter regions located at -
614 and -156, relative to the translation start site, that specifically bind to 
recombinant TRβ1 (unpublished observations).  Furthermore, studies using 
the human gene have suggested the presence of functional TREs between 
–687 and –160 bp upstream of the ATG translation start site [51].   
 
 
 
 
 285 
 
 
 
Acknowledgements 
 
This investigation was supported in part by grant 04 TSP-03 provided 
by the Florida Department of Health (GCN) and Grant # 0555334B from 
the American Heart Association Florida-Affiliate (DL).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 286 
 
 
 
Figures  
 
Fig. 1.  Effects of hypophysectomy and thyroparathyroidectomy on 
mature sterol regulatory element binding protein-2 (SREBP-2) levels in 
rat liver.  Liver nuclear extracts, 10 µg each, from normal, 
hypophysectomized (Hx), and thyroparathyroidectomized (Tx) rats were 
subjected to Western blotting analysis for mature SREBP-2 protein.  Free-
T3 levels in serum samples were determined as described under Materials 
and methods.  “UD” refers to T3 levels too low to be determined.  The 
blots were also probed with TRβ1 specific antibody.  Molecular weight 
markers were applied to one lane.  A representative Western blot is 
presented.  Similar results were obtained in four separate experiments.    
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Fig. 2.  Electrophoretic mobility shift assays depicting binding of rat liver 
nuclear extracts to the rat LDL receptor SRE motif.  32P-labeled rat LDL 
receptor SRE (Rat LDLR SRE) probe was incubated with 10 µg of the 
indicated liver nuclear extract as described in Materials and methods.  
Representative electrophoretic mobility shift assay autoradiographs are 
shown.  “P” refers to a binding reaction performed in the presence of 
probe only.  The position of the SRE/protein complex in each 
autoradiograph has been indicated by an arrow.  A.  Binding of normal 
(N) but not of the thyroparathyroidectomized (Tx) and 
hypophysectomized (Hx) extracts to the SRE.  B.  SREBP-2 specific 
antibody (5 µg IgG) reduces the complex formation between the normal 
liver nuclear extracts (N) and the rat LDL receptor SRE.      
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Fig. 3.  Effects of triiodothyronine (T3) treatment on mature SREBP-2 
protein and LDL receptor mRNA levels in rat liver.   Liver nuclear extracts 
and total RNA from normal and Hx rats treated with T3 for the indicated 
times were analyzed by Western blotting analysis and real-time RT-PCR 
for mature SREBP-2 and LDL receptor mRNA respectively.  A 
representative Western blot is presented.  Similar results were obtained 
in three separate experiments.  The data from the real-time RT-PCR are 
represented as mean relative LDL receptor mRNA levels where the value 
of LDL receptor mRNA for the normal sample was set to 1.0.  Serum 
levels of free-T3 are presented in terms of pg/dl.  Serum cholesterol 
values in mg/dl for each rat are also presented.   
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APPENDIX  
 
LDLRΔ4 cDNA Sequence 
 
 
>LDLR_K-O_LIVER+ANTI-SENSE 
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
TCCTTGATGGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
CACCGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGTCTACCTGTCC
ATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACACGGCCTCCAC
AGCTGAATTGATTGGACTGACAGGTGACAGACATGCATGTCTCTGGG
GACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCATCGCACACCCA
CTTGCTAGCGATGCATTTTCCGTCTCTACACTGGAACTCGTTCCTGCT
GCATGAGTCTTCTA 
 301 
 
  
>LDLR_K-O_LIVER+SENSE 
GGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGCAGCCCCGAGT
GCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCATGTCTGTCACC
TGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCAGCCGATGCAT
TCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGTGAAAATGACT
CAGACGAACAAGGCTGTCCGGTGGCCACCTGCCGACCTGATGAATTC
CAGTGTGCAGATGGCTCCTGCATTCACGGTAGCCGCCAGTGTGACCG
TGAACATGACTGCAAGGACATGAGCGACGAGCTCGGCTGCGTCAATG
TGACACAGTGTGATGGCCCCAACAAGTTCAAGTGTCACAGTGGGGAG
TGCATCAGCTTGGACAAGGTGTGCGACTCCGCCCGCGACTGCCAGGA
CTGGTCGGATGAGCCCATCAAGGAGTGCAAGACCAACGAGTGTTTGG
ACAACAATGGTGGCTGTTCCCACATCTGCAAGGACCTCAAGATTGGC
TCTGAGTGCCTGTA 
  
>NORMAL-LIVER+ANTI-SENSE 
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
 302 
 
TCCTTGATGGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
CACCGCGCAGTGCTCCTCATCTGACTTGTCCTTGCAGTCTGCCTCGCC
GTCACAGACCCAGCTGCGATGGATACACTCACTGCTACCACAGTGGA
ACTCCAGGGAGGAGCAGGGGCTGCTAACGCCTTTGGAGGCCGTGTC
TCGGCCCTGGCAGTTCTGTGGCCACTCATCGGAGCCGTCAACACAGT
CGACATCCCCGTCGCAGGCCCAAAGACTGGGGATGCATATGGATGAG
TTGCAGCGGAAGTGGGCGGGGCCACAAGTGGTGGCCTGGCAGTGGG
CCTCATCAGAGCCATCTAGGCAATCTCGGTCTCCATCACACACAAACT
GCGGGGAGATGCACTTGCCATCCTGGCATCGGAAGTCATCCTGGGA
GCACGTCTTGGGGGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGT
CTACCTGTCCATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACA
CGGCCTCCACAGCTGAATTGATTGGACTGACAGGTGACAGACATGCA
TGTCTCTGGGGACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCAT
CGCACACCCACTTGCTAGCGATGCATTTTCCGTCTCTACACTGGAACT
CGTTCCTGCTGCATGAGTCTTCTA 
 303 
 
  
>NORMAL-LIVER+SENSE 
GGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGCAGCCCCGAGT
GCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCATGTCTGTCACC
TGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCAGCCGATGCAT
TCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGTGAAAATGACT
CAGACGAACAAGGCTGTCCCCCCAAGACGTGCTCCCAGGATGACTTC
CGATGCCAGGATGGCAAGTGCATCTCCCCGCAGTTTGTGTGTGATGG
AGACCGAGATTGCCTAGATGGCTCTGATGAGGCCCACTGCCAGGCCA
CCACTTGTGGCCCCGCCCACTTCCGCTGCAACTCATCCATATGCATCC
CCAGTCTTTGGGCCTGCGACGGGGATGTCGACTGTGTTGACGGCTCC
GATGAGTGGCCACAGAACTGCCAGGGCCGAGACACGGCCTCCAAAG
GCGTTAGCAGCCCCTGCTCCTCCCTGGAGTTCCACTGTGGTAGCAGT
GAGTGTATCCATCGCAGCTGGGTCTGTGACGGCGAGGCAGACTGCA
AGGACAAGTCAGATGAGGAGCACTGCGCGGTGGCCACCTGCCGACC
TGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCACGGTAGCCGCC
AGTGTGACCGTGAACATGACTGCAAGGACATGAGCGACGAGCTCGG
CTGCGTCAATGTGACACAGTGTGATGGCCCCAACAAGTTCAAGTGTC
 304 
 
ACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCGACTCCGCCCG
CGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGAGTGCAAGACC
AACGAGTGTTTGGACAACAATGGTGGCTGTTCCCACATCTGCAAGGA
CCTCAAGATTGGCTCTGAG 
  
>NORMAL-HC+SENSE 
  
GCAGCTGAGAGGAATGCATCGCTAGCAGTGGGTGTGCGATGGCAGC
CCCGAGTGCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCATGTC
TGTCACCTGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCAGCC
GATGCATTCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGTGAA
AATGACTCAGACGAACAAGGCTGTCCCCCCAAGACGTGCTCCCAGGA
TGACTTCCGATGCCAGGATGGCAAGTGCATCTCCCCGCAGTTTGTGT
GTGATGGAGACCGAGATTGCCTAGATGGCTCTGATGAGGCCCACTGC
CAGGCCACCACTTGTGGCCCCGCCCACTTCCGCTGCAACTCATCCAT
ATGCATCCCCAGTCTTTGGGCCTGCGACGGGGATGTCGACTGTGTTG
ACGGCTCCGATGAGTGGCCACAGAACTGCCAGGGCCGAGACACGGC
 305 
 
CTCCAAAGGCGTTAGCAGCCCCTGCTCCTCCCTGGAGTTCCACTGTG
GTAGCAGTGAGTGTATCCATCGCAGCTGGGTCTGTGACGGCGAGGC
AGACTGCAAGGACAAGTCAGATGAGGAGCACTGCGCGGTGGCCACC
TGCCGACCTGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCACGG
TAGCCGCCAGTGTGACCGTGAACATGACTGCAAGGACATGAGCGACG
AGCTCGGCTGCGTCAATGTGACACAGTGTGATGGCCCCAACAAGTTC
AAGTGTCACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCGACTC
CGCCCGCGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGAGTGC
AAGGACCAACGAGTGTTTGCGACAACAATTGGTGGCTGTTCCCACAT
CTGCAAGGACCCGCAGATTTGGCTCTGGAGTTGCCTGGTAAAA 
  
>NORMAL-HC+ANTI-SENSE 
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
TCCTTGATGGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
 306 
 
CACCGCGCAGTGCTCCTCATCTGACTTGTCCTTGCAGTCTGCCTCGCC
GTCACAGACCCAGCTGCGATGGATACACTCACTGCTACCACAGTGGA
ACTCCAGGGAGGAGCAGGGGCTGCTAACGCCTTTGGAGGCCGTGTC
TCGGCCCTGGCAGTTCTGTGGCCACTCATCGGAGCCGTCAACACAGT
CGACATCCCCGTCGCAGGCCCAAAGACTGGGGATGCATATGGATGAG
TTGCAGCGGAAGTGGGCGGGGCCACAAGTGGTGGCCTGGCAGTGGG
CCTCATCAGAGCCATCTAGGCAATCTCGGTCTCCATCACACACAAACT
GCGGGGAGATGCACTTGCCATCCTGGCATCGGAAGTCATCCTGGGA
GCACGTCTTGGGGGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGT
CTACCTGTCCATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACA
CGGCCTCCACAGCTGAATTGATTGGACTGACAGGTGACAGACATGCA
TGTCTCTGGGGACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCAT
CGCACACCCACTTGCTAGCGATGCATTTTCCGTCTCTACACTGGGAAC
TCGTTCCTGCTGCATGGAGTCTTCT 
  
>NORMAL-CORTEX+ANTI-SENSE 
ACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCACTCCTTGAT
GGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTCGCACACC
 307 
 
TTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTTGTTGGGG
CCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGCTCATGTC
CTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGAATGCAGG
AGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGCCACCGCG
CAGTGCTCCTCATCTGACTTGTCCTTGCAGTCTGCCTCGCCGTCACAG
ACCCAGCTGCGATGGATACACTCACTGCTACCACAGTGGAACTCCAG
GGAGGAGCAGGGGCTGCTAACGCCTTTGGAGGCCGTGTCTCGGCCC
TGGCAGTTCTGTGGCCACTCATCGGAGCCGTCAACACAGTCGACATC
CCCGTCGCAGGCCCAAAGACTGGGGATGCATATGGATGAGTTGCAG
CGGAAGTGGGCGGGGCCACAAGTGGTGGCCTGGCAGTGGGCCTCAT
CAGAGCCATCTAGGCAATCTCGGTCTCCATCACACACAAACTGCGGG
GAGATGCACTTGCCATCCTGGCATCGGAAGTCATCCTGGGAGCACGT
CTTGGGGGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGTCTACCTG
TCCATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACACGGCCTC
CACAGCTGAATTGATTGGACTGACAGGTGACAGACATGCATGTCTCT
GGGGACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCATCGCACA
CCCACTTGCTAGCGATGCATTTTCCGTCTCTACACTGGGAACTCGTTC
CTGCTGCATGGAGGTCTTCTCG 
  
 308 
 
>NORMAL-CORTEX+ SENSE 
GTGTAGAGACGGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGC
AGCCCCGAGTGCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCAT
GTCTGTCACCTGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCA
GCCGATGCATTCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGT
GAAAATGACTCAGACGAACAAGGCTGTCCCCCCAAGACGTGCTCCCA
GGATGACTTCCGATGCCAGGATGGCAAGTGCATCTCCCCGCAGTTTG
TGTGTGATGGAGACCGAGATTGCCTAGATGGCTCTGATGAGGCCCAC
TGCCAGGCCACCACTTGTGGCCCCGCCCACTTCCGCTGCAACTCATC
CATATGCATCCCCAGTCTTTGGGCCTGCGACGGGGATGTCGACTGTG
TTGACGGCTCCGATGAGTGGCCACAGAACTGCCAGGGCCGAGACAC
GGCCTCCAAAGGCGTTAGCAGCCCCTGCTCCTCCCTGGAGTTCCACT
GTGGTAGCAGTGAGTGTATCCATCGCAGCTGGGTCTGTGACGGCGA
GGCAGACTGCAAGGACAAGTCAGATGAGGAGCACTGCGCGGTGGCC
ACCTGCCGACCTGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCA
CGGTAGCCGCCAGTGTGACCGTGAACATGACTGCAAGGACATGAGC
GACGAGCTCGGCTGCGTCAATGTGACACAGTGTGATGGCCCCAACAA
GTTCAAGTGTCACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCG
ACTCCGCCCGCGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGA
 309 
 
GTGCAAGACCAACGAGTGTTTGGACAACAATGGTGGCTGTTCCCACA
TCTGCAAGGACCTCAAGATTGGCTCTGAGTGCCT 
  
>LDLR_K-O-CORTEX+ANTI-SENSE 
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
TCCTTGATGGGCTCATCCGACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
CACCGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGTCTACCTGTCC
ATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACACGGCCTCCAC
AGCTGAATTGATTGGACTGACAGGTGACAGACATGCATGTCTCTGGG
GACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCATCGCACACCCA
CTTGCTAGCGATGCATTTTCCGTCTCTACACTGGAACTCGTTCCTGCT
GCATGAGTCTTCT 
  
 310 
 
>LDLR_K-O-CORTEX+ SENSE 
  
GTGTAGAGACGGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGC
AGCCCCGAGTGCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCAT
GTCTGTCACCTGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCA
GCCGATGCATTCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGT
GAAAATGACTCAGACGAACAAGGCTGTCCGGTGGCCACCTGCCGACC
TGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCACGGTAGCCGCC
AGTGTGACCGTGAACATGACTGCAAGGACATGAGCGACGAGCTCGG
CTGCGTCAATGTGACACAGTGTGATGGCCCCAACAAGTTCAAGTGTC
ACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCGACTCCGCCCG
CGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGAGTGCAAGACC
AACGAGTGTTTGGACAACAATGGTGGCTGTTCCCACATCTGCAAGGA
CCTCAAGATTGGCTCTGAGTGCCTGT 
  
>LDLR_K-O--HC+ANTI-SENSE 
ATGTGGGAACAGCCACCATTGTTGTCCAAACACTCGTTGGTCTTGCAC
 311 
 
TCCTTGATGGGCTCATCCAACCAGTCCTGGCAGTCGCGGGCGGAGTC
GCACACCTTGTCCAAGCTGATGCACTCCCCACTGTGACACTTGAACTT
GTTGGGGCCATCACACTGTGTCACATTGACGCAGCCGAGCTCGTCGC
TCATGTCCTTGCAGTCATGTTCACGGTCACACTGGCGGCTACCGTGA
ATGCAGGAGCCATCTGCACACTGGAATTCATCAGGTCGGCAGGTGGC
CACCGGACAGCCTTGTTCGTCTGAGTCATTTTCACAGTCTACCTGTCC
ATCACATCTCCAGGAGTCAGGAATGCATCGGCTGACACGGCCTCCAC
AGCTGAATTGATTGGACTGACAGGTGACAGACATGCATGTCTCTGGG
GACTCATCGGAGCCATCCGGGCACTCGGGGCTGCCATCGCACACCCA
CTTGCTAGCGATGCATTTTCCGTCTCTACACTGGAACTCGTTCCTGCT
GCATGAAGTCTTCT 
>LDLR_K-O--HC+ SENSE 
  
GTGTAGAGACGGAAAATGCATCGCTAGCAAGTGGGTGTGCGATGGC
AGCCCCGAGTGCCCGGATGGCTCCGATGAGTCCCCAGAGACATGCAT
GTCTGTCACCTGTCAGTCCAATCAATTCAGCTGTGGAGGCCGTGTCA
GCCGATGCATTCCTGACTCCTGGAGATGTGATGGACAGGTAGACTGT
GAAAATGACTCAGACGAACAAGGCTGTCCGGTGGCCACCTGCCGACC
 312 
 
TGATGAATTCCAGTGTGCAGATGGCTCCTGCATTCACGGTAGCCGCC
AGTGTGACCGTGAACATGACTGCAAGGACATGAGCGACGAGCTCGG
CTGCGTCAATGTGACACAGTGTGATGGCCCCAACAAGTTCAAGTGTC
ACAGTGGGGAGTGCATCAGCTTGGACAAGGTGTGCGACTCCGCCCG
CGACTGCCAGGACTGGTCGGATGAGCCCATCAAGGAGTGCAAGACC
AACGAGTGTTTGGACAACAATGGTGGCTGTTCCCACATCTGCAAGGA
CCTCAAGATTGGCTCTGAGTGCCTGT 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
About the Author 
 
Jose Abisambra was born in Miami, FL and raised in Santa Marta 
and Buenaventura, Colombia. He graduated high school from el Colegio 
San Carlos and nurtured his interest in neuroscience at la Pontificia 
Universidad Javeriana. In 2000, he relocated to Florida, where he earned 
a Bachelor’s of Science degree in Biology from Saint Leo University 
(2002) and a Master’s of Science degree from the University of South 
Florida (2004) for his work on LDLR activation by thyroid hormone.  
 
Jose joined Dr. Huntington Potter’s Alzheimer’s research laboratory 
in 2004 to pursue a Doctoral degree in Medical Sciences. During his time 
in Dr. Potter’s lab, Jose investigated the links between cholesterol and 
Alzheimer’s disease from the perspective of the LDLR. He presented his 
work in national and international conferences such as the Society for 
Neuroscience Conferences every year since 2007, in the Colegio 
Colombiano de Neurociencias Conference in Bogota, Colombia in 2008, as 
a guest seminar speaker at the Mayo Clinic, Jacksonville, FL in 2009, La 
Universidad Jorge Tadeo Lozano in Santa Marta, Colombia, and finally in 
La Academia de Medicina de Cartagena, Colombia in 2010 where he was 
inducted as a member.  
